S hire C O N FI D E N TI A L Pa ge 3
S H P 6 3 4 -1 0 2 Pr ot oc ol 
N at p ar a 2 9 J a n 2 0 1 7 
E M E R G E N C Y  C O N T A C T I N F O R M A TI O N 
I n t he e ve nt of a seri o us a d verse e ve nt ( S A E), t he i n vesti gat or m ust fa x or e - mail t he S hire 
Cli nical St u d y  Seri o us A d verse E ve nt a n d N o n- seri o us A Es Re q uire d b y  t he Pr ot oc o l F or m 
wit hi n 2 4 h o urs t o t he S hire Gl o bal Dr u g Safet y De part me nt. A p plica ble fa x n u m bers a n d e -mail 
a d dress ca n be f o u n d o n t he f or m (se nt u n der se parate c o ver). A c o p y of t his f or m m ust als o be 
se nt t o t he c o ntract researc h or ga nizati o n ( C R O)/ S hire me dic al m o nit or b y  e mail usi n g t he 
details bel o w. 
E- mail: 
F or pr ot oc ol -or s afet y -rel ate d iss ues, t he i n vesti g at or m ust c o nt act t he S hire Me dic al 
M o nit or: P P D 
 D D S, P h. D. 
Tele p h o ne:  ( b usi ness h o urs) 
 ( 2 4 -h o ur c o vera ge) P P D 
P P D 
P P D 
S hire C O N FI D E N TI A L Pa ge 4
S H P 6 3 4 -1 0 2 Pr ot oc ol 
N at p ar a 2 9 J a n 2 0 1 7 
A D DI TI O N A L  C O N T A C T I N F O R M A TI O N 
I n c ase of a n y ot her iss ues, i ncl u di n g n o n -s afet y rel ate d iss ues or if t he me dic al m o nit or is 
u n a ble t o be re ac he d, t he i n vesti g at or m ust c o nt act t he S hire St u d y M a n a ger: 
P P D 
St u d y  Ma na ger 
Te le p h o ne:  ( b usi ness h o urs) 
 ( 2 4 -h o ur c o vera ge) 
E mail: 
If u na vaila ble, please c o ntact: 
Cli nical P har mac ol o g y  Gr o u p Lea d 
Tele p h o ne:  ( b usi ness h o urs) 
 ( 2 4 -h o ur c o v era ge) 
E mail: P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
S hire C O N FI D E N TI A L Pa ge 5
S H P 6 3 4 -1 0 2 Pr ot oc ol 
N at p ar a 2 9 J a n 2 0 1 7 
P R O D U C T Q U A LI T Y  C O M P L AI N T S 
I n vesti gat ors are re q uire d t o re p ort i n vesti gati o nal pr o d uct q ualit y  c o m plai nts t o S hire wit hi n 2 4 
h o urs. T his i ncl u des a n y  i nsta nces w herei n t he q ualit y  o r perf or ma nce of a S hire pr o d uct 
( mar kete d or i n vesti gati o nal) d oes n ot meet e x pectati o ns (e g, i na de q uate or fa ult y  c l os ure, 
pr o d uct c o nta mi nati o n) or t hat t he pr o d uct di d n ot meet t he s pecificati o ns defi ne d i n t he 
a p plicati o n f or t he pr o d uct (e g, wr o n g pr o d uct s uc h t hat t he la bel a n d c o nte nts are differe nt 
pr o d ucts). F or i nstr ucti o ns o n re p orti n g A Es relate d t o pr o d uct  c o m plai nts, see Secti o n 8.
Please use t he i nf or mati o n bel o w as a p plica ble t o re p ort t he Pr o d uct Q ualit y C o m plai nt: 
Ori gi n of Pr o d uct Q u alit y C o m pl ai nt E-m ail A d dress 
N ort h a n d S o ut h A merica 
E ur o pea n U ni o n a n d Rest of W orl d 
P P D Tele p h o ne n u m bers ( pr o vi de d f or refere nce if nee de d): 
S hire, Le xi n gt o n, M A ( U S A) P P D 
P P D 
Shire CONFIDENTIAL Page 6
SHP634 -102 Protocol
Natpara 29Jan 2017
TABLE OF CONTENTS
PROTOCOL  SIGNATURE P AGE .................................................................................................2
EMERGENCY CONTACT I NFORMATION ................................................................................3
ADDITIONAL CONTACT I NFORMATION ................................................................................4
PRODUCT QUALITY COMP LAINTS ..........................................................................................5
LIST OF TABLES .........................................................................................................................10
LIST OF FIGURES .......................................................................................................................10
LIST OF AP PENDICES ................................................................................................................10
ABBREVIAT IONS .......................................................................................................................11
STUDY SYNOPSI S
......................................................................................................................13
STUDY SCHEDULE(S) ...............................................................................................................20
1.BACKGROUND INFORMATI ON.......................................................................................25
1.1 Indication and Current Treatment Options ...............................................................26
1.2 Product Background .................................................................................................26
1.2.1 Preclinical Information ..........................................................................................26
1.2.2 Clinical I nformation ...............................................................................................27
1.3 Risk/Benefit and Ethical Assessment .......................................................................28
2.STUDY OBJECTIVES AND PURPOSE ..............................................................................30
2.1 Rationale for the Study .............................................................................................30
2.2 Study  Objectives ......................................................................................................30
2.2.1
Primary  Objective ..................................................................................................30
2.2.2 Secondary  Objectives .............................................................................................30
3.STUDY DESIGN ...................................................................................................................32
3.1 Study  Design and Flow Chart ..................................................................................32
3.2 Rationale for Dose Selection and Study  Design Elements ......................................35
3.3 Duration and Study  Completion Definition ................................ ............................. 35
3.4 Sites and Regions .....................................................................................................36
4.STUDY POPUL ATION................................ ................................ ................................ ......... 37
4.1 Inclusion Criteria................................ ................................ ................................ ......37
4.2 Exclusion Criteria ................................ ................................ ................................ .....38
4.3 Restrictions ................................ ................................ ................................ ............... 39
4.4 Reproductive Potential .............................................................................................40
4.4.1 Female Contraception ................................ ................................ ............................ 40
4.4.2 Male Contraception ................................ ................................ ................................ 41
4.5 Discontinuation of Subjects ................................ ................................ ..................... 41
4.5.1 Reasons for Discontinuation ................................ ................................ .................. 41
Shire CONFIDENTIAL Page 7
SHP634 -102 Protocol
Natpara 29Jan 2017
4.5.2 Subjects “L ost to Follow -up” Prior to Last Scheduled Visit .................................42
5.PRIOR AND CONCOMITAN T TREATMENT ...................................................................43
5.1 Prior Treatment ........................................................................................................43
5.2 Concomitant Treatment ............................................................................................43
5.2.1 Permitted Treatment ...............................................................................................43
6.INVESTIGAT IONAL PROD UCT ........................................................................................44
6.1 Identity  of Investigational Product ...........................................................................44
6.1.1 Blinding the Treatment Assignment ......................................................................44
6.2 Administration of I nvestigational Product(s) ...........................................................44
6.2.1 Allocation of Subjects to Treatment ......................................................................44
6.2.2 Dosing ....................................................................................................................45
6.2.3 Unblinding the Treatment Assignment ..................................................................45
6.3
Labeling, Packaging, Storage, and Handling ...........................................................45
6.3.1 Labeling .................................................................................................................45
6.3.2 Packaging ...............................................................................................................46
6.3.3 Storage ...................................................................................................................46
6.4 Drug Accountability .................................................................................................46
6.5 Subject Compliance ..................................................................................................47
6.6 Retention of Bioavailability  and Bioequivalence Testing Samples .........................47
7.
STUDY PROCEDURES........................................................................................................48
7.1 Study  Schedule .........................................................................................................48
7.1.1 Screening Period ....................................................................................................48
7.1.1.1 Screening Failure ....................................................................................48
7.1.1.2 Rescreening of Subjects .........................................................................48
7.1.2 Treatment Period ....................................................................................................49
7.1.2.1 Days 1 to 8 ..............................................................................................49
7.1.2.2 Final Visit ...............................................................................................49
7.1.3 Follow -up Period ...................................................................................................49
7.1.4 Additional Care of Subjects after the Stud y
................................ .......................... 49
7.2 Study  Evaluations and Procedures ................................ ................................ ........... 49
7.2.1 Demographic and Other Bas eline Characteristics ................................ ................. 49
7.2.1.1 Demographics .........................................................................................49
7.2.2 Safety ................................ ................................ ................................ ..................... 50
7.2.2.1 Medical and Medication History ................................ ............................ 50
7.2.2.2 Physical Examination (Including Height and Weight) ..........................50
7.2.2.3
Adverse Event Collection................................ ................................ .......51
7.2.2.4 Vital Signs ................................ ................................ .............................. 51
7.2.2.5 Clinical L aboratory  Evaluations ................................ ............................. 53
Shire CONFIDENTIAL Page 8
SHP634 -102 Protocol
Natpara 29Jan 2017
7.2.2.6 Pregnancy  Test .......................................................................................54
7.2.2.7 Drug and Alco
hol Screen .......................................................................54
7.2.2.8 Serology  Screen ......................................................................................55
7.2.2.9 Electrocardiogram ..................................................................................55
7.2.3 Pharmacokinetic Procedures ..................................................................................56
7.2.3.1 Pharmacokinetic Sample Collection and Handling Procedures .............56
7.2.3.2 Shipment of Plasma Pharmacokinetic Samples .....................................57
7.2.3.3 Plasma Drug Assay  Methodology ..........................................................57
7.2.4 Pharmacod ynamic Assessments ............................................................................57
7.2.4.1 Pharmacod ynamic Sample Collection and Handling Proced ures..........57
7.2.4.2 Shipment of Serum Pharmacod ynamic Samples ...................................58
7.2.4.3 Serum Pharmacod ynamic Assay  Methodology .....................................58
7.2.5 Immunogenicit y Testing for Anti -Parath yroid Hormone Antibodies ....................58
7.2.5.1 Sample Collection and Handling Procedures for Immunogenicit y 
Testing for Anti -Parath yroid Hormone Antibodies
................................59
7.2.5.2 Anti- Parath yroid Hormone Antibody Assay Methodology
...................59
7.2.6 Volume of Blood to Be Drawn from Each Subject ...............................................60
8.ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................61
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................61
8.1.1 Severi ty Categorization ..........................................................................................61
8.1.2 Relationship Categorization ...................................................................................62
8.1.3 Outcome Categorization ........................................................................................62
8.1.4 Clinical L aboratory  and Other Safet y Evaluations ................................................62
8.1.5 Pregnancy ...............................................................................................................63
8.1.6 Abuse, Misuse, Overdose, and Medication Error ..................................................63
8.2 Serious Adverse Event Procedures ..........................................................................64
8.2.1 Reference Safet y Information ................................................................................64
8.2.2 Reporting Procedures ................................ ................................ ............................. 64
8.2.3 Serious Adverse Event Definition ................................ ................................ ......... 65
8.2.4 Serious Adverse Event Collection Time Frame ................................ ..................... 65
8.2.5 Serious Adverse Event Onset and Resolution Dates .............................................65
8.2.6 Fatal Outcome ................................ ................................ ................................ ........ 66
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, and Site 
Reporting................................................................................................................66
9.DATA MANAGEMENT AND STATISTICAL METHODS
................................ ............... 67
9.1 Data Collection ................................ ................................ ................................ ......... 67
9.2 Clinical Data Management ................................ ................................ ....................... 67
Shire CONFIDENTIAL Page 9
SHP634 -102 Protocol
Natpara 29Jan 2017
9.3 Data Handling Considerations..................................................................................67
9.4 Statistical Analy
sis Process ......................................................................................67
9.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Com mittee ......67
9.6
Sample Size Calculation and Power Considerations................................................68
9.7 Study  Population ......................................................................................................68
9.8 Pharmacokine tic and Pharmacod ynamic Anal yses..................................................68
9.8.1 Pharmacokinetic Analy sis......................................................................................68
9.8.1.1 Statistical Analy sis of Pharmacokinetic Parameters ..............................69
9.8.2 Pharmacod ynamic Anal ysis...................................................................................69
9.8.3 Statistical Analy sis of Pharmacod ynamic Values ..................................................70
9.9 Safety  Anal yses........................................................................................................70
9.9.1 Safety
 Endpoint(s) .................................................................................................70
9.9.2 Statistical Methodology  for Safet y Endpoint(s) ....................................................70
9.10 Other Anal yses.........................................................................................................71
10.SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES...........................................72
10.1
Sponsor’s Responsibilities .......................................................................................72
10.1.1 Good Clinical Practice Comp
liance .......................................................................72
10.1.2 Indemnity /Liability  and Insurance .........................................................................72
10.1.3 Public Posting of Study  Information ......................................................................72
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................72
10.1.5 Study  Suspension, Termination, and Completion
..................................................73
10.2 Investigator’s Responsibilities .................................................................................73
10.2.1 Good Clinical Practice Compliance .......................................................................73
10.2.2 Protocol Adherence and Investigator Agre ement ..................................................73
10.2.3 Documentation and Retention of Records .............................................................74
10.2.3.1 Case Report Forms .................................................................................74
10.2.3.2 Recording , Access, and Retention of Source Data and Study  
Documents ..............................................................................................74
10.2.3.3 Audit/I nspection ................................ ................................ ..................... 75
10.2.3.4 Financial Disclosure ................................ ................................ ............... 75
10.3 Ethical Considerations ..............................................................................................75
10.3.1 Informed Consent ................................ ................................ ................................ ...75
10.3.2 Institutional Review Board or Ethics Committee ................................ .................. 75
10.4 Privacy  and Confidentiality ................................ ................................ ...................... 76
10.5 Study  Results/Publication Policy ................................ ................................ ............. 77
11.REFERENCES ................................ ................................ ................................ ....................... 79
12.APPENDI CES ................................ ................................ ................................ ........................ 81
Shire CONFIDENTIAL Page 10
SHP634 -102 Protocol
Natpara 29Jan 2017
LIST  OF TABLES
Table 1 Schedule of Assessments ...............................................................................20
Table 2 Detailed Schedule of Assessments (non
-Hispanic, Caucasian Subjects) ......23
Table 3 Detailed Schedule of Assessments (Subjects of Japanese Descent) .............24
Table 4 Volume of Blood to Be Drawn from Each Su bject .......................................60
LIST  OF FIGURES
Figure 1 Study  Design Flow Chart ..............................................................................34
Figure 2 Procedures for Screening Vital Signs (Blood Pressure –Pulse)...................52
LIST  OF APPENDICES
Appendix 1
Protocol History .....................................................................................81
Shire CONFIDENTIAL Page 11
SHP634 -102 Protocol
Natpara 29Jan 2017
ABBREVIA TIONS
z first order rate constant associated with the terminal (log linear) portion of 
the curve
%CV percent coefficient of geometric mean
AE adverse event
AUC last area under the curve from the time of dosing to the last measurable 
concentration
-hCG beta-human chorionic gonadotropin
BP blood pressure
CaSR calcium -sensing receptor
CI confi dence interval
CL/F apparent clearance
Cmax maximum concentration occurring at t max
CO 2 carbon dioxide
CRC clinical research center
CRF case report form
CRO contract research organization
CV% coefficient of variation
DMC data monitoring committee
EC ethics committee
ECG electrocardiogram
EMA European Medicines Agency
Emax maximum effect
EU European Union
FDA Food and Drug Administration
FSH follicle stimulating hormone
GCP Good Clinical Practice
HBsAg hepatitis B surface antigen
HCV hepati tis C virus
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency virus
ICH International Conference on Harmonisation
ICMJE International Committee of Medical Journal Editors
IRB Institutional Review Board
Shire CONFIDENTIAL Page 12
SHP634 -102 Protocol
Natpara 29Jan 2017
MHL W Ministry of Health, Labor and Welfare
PD pharmacod ynamic
pH potentia hy drogenii (measure of acidity /alkalinit y)
PK pharmacokinetic
PMDA Pharmaceuticals Medical Devices Agency
PR time elapsed from P wave to R wave in an electrocardiogram
PTH parath yroid hormo ne
QTcB measure of time between the start of the Q wave and the end of the T wave 
using Bazett’s formula in an electrocardiogram
QD quaque die (once a day )
QRS measure of time for the 3 main deflections in an electrocardiogram
QT measure of time betwee n the start of the Q wave and the end of the T wave 
in an electrocardiogram
QTcF measure of time between the start of the Q wave and the end of the T wave 
using Fridericia’s formula in an electrocardiogram
rhPTH recombinant human parathy roid hormone
RR the time between heart beats in an electrocardiogram
SAE serious adverse event
SAP statistical analy sis plan
SAS statistical analy sis software
SC subcutaneous
SD standard deviation
t½ terminal half -life
T3 triiodothy ronine
T4 thyroxine
TEAE treatm ent emergent adverse event
TEmax time to maximum effect
tmax time of maximum observed concentration sampled during a dosing 
interval
TSH thyroid stimulating hormone
UK United Kingdom
US United States
Vdz/F apparent volume of distribution
S hire C O N FI D E N TI A L Pa ge 1 3 
S H P 6 3 4 -1 0 2 Pr ot oc ol 
N at p ar a 2 9 J a n 2 0 1 7 
S T U D Y  S Y N O P SI S 
Pr ot oc ol n u m ber: 
S H P 6 3 4 -1 0 2 Dr u g: 
Rec o m bi na nt H u ma n Parat h yr oi d H or m o ne (r h P T H[ 1 -8 4]) 
Title of t he st u d y: 
A P hase 1, O pe n -la bel, Ra n d o mize d, Cr oss - o ver St u d y t o E val uate t he P har mac o ki netics, Safet y, a n d T olera bilit y of 
a Si n gle D ose of  r h P T H( 1 -8 4) A d mi nistere d S u bc uta ne o usl y i n Ja pa nese Healt h y S u bjects C o m pare d wit h Matc he d 
N o n -His pa nic, Ca ucasia n  H ealt h y A d ult S u bjects a n d t o Assess D ose Pr o p orti o nalit y of 3D oses of r h P T H( 1 -8 4) i n 
t he Ja pa nese S u bjects 
N u m ber of s u bjects (t ot al a n d f or e ac h tre at me nt ar m): 
A t otal of 2 4 healt h y, a d ult, male a n d/ or fe male s u bjects will be e nr olle d i nt o t he st u d y, c o m prisi n g 1 2 s u bjects of 
Ja pa nese desce nt a n d 1 2 matc he d, n o n- His pa nic, Ca ucasia n s u bjects. St u d y s u bjects w h o wit h dra w  o r disc o nti n ue 
earl y ma y be re pla ce d at t he discreti o n of t he s p o ns or. N o n -His pa nic, Ca ucasia n s u bjects will be matc he d t o s u bjects 
of Ja pa nese desce nt base d o n se x ( 1: 1 male: fe male), a ge ( 5 years), wei g ht ( 1 0 %), a n d b o d y mass i n de x ( 1 5 %) 
 T he s u bjects of Ja pa nese desce nt will be e x p ose d t o 3, ra n d o mize d, cr oss -o ver si n gle d oses of 
r h P T H( 1 -8 4) at 2 5 µ g, 5 0 µ g a n d 1 0 0 µ g. 
 Matc he d, n o n -His pa nic, Ca ucasia n  s u bjects wi ll be e x p ose d t o a si n gle d ose of r h P T H( 1 -8 4) at 
1 0 0 µ g. 
I n vesti g at or(s): 
,M D 
Site(s) a n d Re gi o n(s): 
P A R E X E L 
Gle n dale A d ve ntist Me dical Ce nter 
1 5 6 0 E. C he v y C hase Dri ve 
S uite 1 4 0 
Gle n dale, C A, 9 1 2 0 6, U S A 
St u d y peri o d ( pl a n ne d): 
M a y  2 0 1 7 -J u ne 2 0 1 7 Cli nic al p h ase: 1
Objecti ves: 
Pri m ar y: 
 T o c o m pare t he p har mac o ki netic ( P K) pr ofile of rec o m bi na nt h u ma n parat h yr oi d h or m o ne 
(r h P T H[ 1 -8 4]), a d mi nistere d as a si n gle s u bc uta ne o us ( S C) d ose of 1 0 0 μ g, bet w ee n healt h y a d ult 
v ol u nteer s u bjects of Ja pa nese desce nt a n d matc he d, n o n -His pa nic, healt h y, a d ult Ca ucasia n  
s u bjects. 
Sec o n d ar y: 
 T o assess t he d ose pr o p orti o nalit y of t he P Ks of r h P T H( 1 -8 4) i n healt h y a d ult v ol u nteer s u bjects 
of Ja pa nese de sce nt w he n e x p ose d t o si n gle S C d oses of r h P T H( 1 -8 4) at 2 5 µ g, 5 0 µ g a n d 1 0 0 µ g. 
 T o c o m pare t he p har mac o d y na mic ( P D) pr ofile (i ncl u di n g meas ure me nt of ser u m calci u m a n d 
p h os p hate le vels) of a 1 0 0 μ g S C i njecti o n of r h P T H( 1 -8 4) i n healt h y a d ult v ol u nteer s u bjec ts of 
Ja pa nese desce nt a n d matc he d, n o n -His pa nic, healt h y, a d ult Ca ucasia n s u bjects. 
 T o assess t he P D pr ofile (i ncl u di n g meas ure me nt of ser u m calci u m a n d p h os p hate le vels) of a 
2 5 μ g a n d 5 0 µ g S C i njecti o n of r h P T H( 1 -8 4) i n healt h y a d ult v ol u nteer s u bjects o f Ja pa nese P P D 
Shire CONFIDENTIAL Page 14
SHP634 -102 Protocol
Natpara 29Jan 2017
descent.
 To assess the safety and tolerability of single SC doses of 25µg, 50µg, and 100µg of rhPTH(1 -84) 
in healthy adult volunteer subjects of Japanese descent.
 To evaluate the safety and tolerability of a single 100µg SC injection of rhPTH(1 -84) in matched, 
non-Hispanic, healthy, adult volunteer Caucasian  subjects.
Rationale:
This study is being conducted to evaluate the PK, PD, safety and tolerability of rhPTH(1 -84) after single -dose SC 
administration in adult healthy volunteers of Japanese descent in comparison with adult, healthy, non -Hispanic, 
Caucasian volunteers. In addition, this study will assess the PK dose- proportionality and similarity of rhPTH(1 -84) 
in  healthy volunteers of Japanese descent as compared with historical data obta ined in  non -Japanese healthy 
volunteers.
The Japanese regulatory agencies, Pharmaceuticals Medical Devices Agency (PMDA) and the Ministry of Health, 
Labor and Welfare (MHLW) require evidence that current data in non -Japanese subjects can be extrapolated t o the 
Japanese population.
This study can be conducted in a facility that is located outside of the country of Japan as long as steps are taken to 
ensure that the subjects w ill be viewed as Japanese (or of direct Japanese descent).
The results from this s tudy will be utilized to guide dose selection for a future Phase 3 study in Japanese patients 
with hypoparathyroidism.
Investigational product, dose, and m ode of administration: The investigational product (rhPTH[1 -84]) is a 
lyophilized pow der form of rec ombinant human parathyroid hormone produced from genetically modified 
Escherichia coli and contained w ithin a glass cartridge that includes sterile diluent as well. The investigational 
product is reconstituted w ithin the glass cartridge and administered fr om an injector pen (Haselmeier) as a SC 
injection at doses of 25µg, 50µg and 100µg into the mid -thigh (100µg only in non -Hispanic, Caucasian subjects). 
The volume of reconstituted drug administered at 1 dose is 71.4µL.This study is open -label and does not require the 
use of a placebo.
Methodology:
This is a Phase 1, open -label, randomized, cross -over, single -center study to evaluate the PK and PD profiles and 
safety and tolerability of rhPTH(1 -84) administered in healthy adult volunteer subjects of Japanes e descent and 
matched non -Hispanic, Caucasian healthy adult volunteer subjects. The non -Hispanic, Caucasian volunteers will 
receive a single dose of 100µg rhPTH(1 -84). The Japanese subjects w ill receive 3 single doses of rhPTH(1 -84). On 
Day 1 the subjects of Japanese descent will receive a single SC injection of 100µg. On Days 4 and 7 the subjects of 
Japanese descent will be randomized to receive a single SC injection of either 25µg or 50µg. such that all of these 
subjects are exposed to the 3 dose strength s over a 7 day period to further characterize the PK profile in that group. 
A total of 24 subjects w ill be enrolled: 12 non -Hispanic, Caucasian subjects and 12 subjects of Japanese descent (1:1 
male: female). Non -Hispanic, Caucasian subjects will be matched to Japanese subjects based on sex, age ( 5 years), 
weight ( 10%), and body mass index ( 15%). 
All subjects will receive a single dose of 100μg rhPTH(1 -84) administered by SC injection in the mid -thigh with the 
Haselmeier injector pen on Day 1. In additi on, the subjects of Japanese descent will also receive single dose 
injections of 25µg and 50µg rhPTH(1 -84) administered by SC injection in the mid -thigh to characterize the PK 
profile over a range of doses. There w ill be a minimum of 72 hours (maximum 73 h ours) washout from single dose 
to single dose for the volunteers of Japanese descent. The study duration will comprise of a 28 -day screening period, 
1 treatment period for the non -Hispanic, Caucasian group (Days 1 and 2); 1 treatment period for the volunte ers of 
Japanese descent (Days 1 -8), and a follow -up visit (30±2 days) after the last dose of investigation drug is 
administered for each subject. The total number of nights subjects will be expected to stay at the clinical research 
center (CRC) is 2 for th e non -Hispanic, Caucasian group and 8 for the volunteers of Japanese descent. The maximal 
total duration of study participation for a non -Hispanic, Caucasian subject is 62 days and 68 days for the volunteers 
of Japanese descent, if the maximum screening, t reatment and follow -up visit durations are used.
Screening will occur within 28 days of the first dose. Subjects will be admitted to the CRC on Day -1.
Shire CONFIDENTIAL Page 15
SHP634 -102 Protocol
Natpara 29Jan 2017
Treatment Periods:
On Day 1, all study subjects will receive rhPTH(1 -84) as a single 100μg SC injection in the mid -thigh.
On Day 4, and Day 7, all subjects of Japanese descent will receive rhPTH(1 -84) as a single SC injection in 
the mid -thigh of either 25µg or 50µgdepending upon randomization assignment. Administration of 
rhPTH(1 -84) in subjects of Japanese descent in the mid -thigh should be randomized locally so that an equal 
number of subjects receive the first dose in the right thigh and an equal number in the left thigh. 
Subsequent doses should be administered in the opposing thigh to the last dose.
Asse ssments
 Serial blood samples for PK analysis will be collected on Day 1 (and Day 4 and Day 7 for the 
subjects of Japanese descent) for the determination of parathyroid hormone (PTH) concentrations 
(original and baseline -adjusted) at pre -dose and up to 24 h ours post dose. These blood samples 
will be collected according to the Schedule of Assessments.
 Serial blood samples for PD analysis will be collected on Day 1 (and Day 4 and Day 7 for the 
subjects of Japanese descent) at pre -dose and up to 24 hours post d ose for the determination of 
serum calcium, phosphate, and albumin concentrations.
 Safety and tolerability will be determined through assessment of treatment -emergent adverse 
events (TEAEs) and vital signs, electrocardiogram (ECG) findings, and clinical la boratory 
evaluations on Day 1 pre- dose and up to 24 hours post dose for the non -Hispanic, Caucasian 
subjects and Day 1 pre- dose and up to 24 hours post last dose (Day 8) for the subjects of Japanese 
descent.
 Additional blood samples for safety purposes wil l be collected for assessment of anti -PTH  
antibodies.
Follow -up
A post treatment follow -up visit w ill be completed 30 (± 2) days after the last dose of investigational product for 
each subject.
Inclusion and exclusion criteria:
Inclusion Criteria:
1.Ability to voluntarily provide written, signed, and dated informed consent as applicable to participate in the 
study.
2.An understanding, ability, and w illingness to fully comply with study procedures and restrictions.
3.Age 18 -65, inclusive, at the time of consent. The date of signature of the informed consent is defined as the 
beginning of the screening period. This inclusion criterion will only be assessed at the first screening visit.
4.Subjects must be either:
a)A subject of Japanese descent born in Japan, who has resided outside of Japan for no longer than 5 
years and is of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese 
grandparents, all born in Japan.
b)A non-Hispanic, Caucasian subject who has 2 non -Hispanic, Caucasian parents and 4 
non-Hisp anic, Caucasian grandparents.
5.Male or nonpregnant, nonlactating female who agrees to comply with any applicable contraceptive 
requirements of the protocol or females of nonchildbearing potential.
6.Considered “healthy” by the investigator.  Healthy status is defined by absence of evidence of any active or 
chronic disease following a detailed medical and surgical history, a complete physical examination 
including vital signs, 12 -lead ECG, hematology, blood chemistry, and urinalysis.
7.Body  mass index between 18. 5 and 25 kg/m², inclusive, with a body weight ≥45kg (99lbs). This inclusion 
Shire CONFIDENTIAL Page 16
SHP634 -102 Protocol
Natpara 29Jan 2017
criterion w ill only be assessed at the first screening visit.
8.Willing and able to consume standardized meals during the confinement period of the study. All participants 
will be r equired to consume the identical meals on study days when serial PK and PD blood samples are 
collected.
9.A clinical safety laboratory parameter of hemoglobin greater than 11.7g/dl (females) or 13.1g/dl (males) 
and less than 16g/dl (females) or 17.4g/dl (mal es).
10.Total serum calcium within laboratory normal limits.
11.Serum parathyroid hormone (PTH) levels within laboratory normal limits.
Exclusion Criteria:
1.History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric di sease, 
gall bladder removal, or current or recurrent disease that could affect the action, absorption, or disposition 
of the investigational product, or clinical or laboratory assessments.
2.Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment 
or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the 
investigational product or procedures.
3.Known or suspected intolerance or hypersensitivity to the inves tigational product(s), closely -related 
compounds, or any of the stated ingredients.
4.Significant illness, as judged by the investigator, within 2 weeks of the first dose of investigational product.
5.Known history of alcohol or other substance abuse within th e last year.
6.Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to receiving the first dose 
of investigational product.
7.Use of the following prior to administration of investigational product w ithin:
30 days –loop diuretics , lithium, antacids, systemic corticosteroids (medical judgment is required 
by the investigator. Primarily high doses of systemic corticosteroids [eg, prednisone] should be 
excluded. Stable doses of hydrocortisone [eg, as treatment for Addison’s disease] m ay be 
acceptable).
3 months –calcitonin, cinacalcet hydrochloride, treatment with rhPTH(1 -84) or N -terminal PTH 
or PTH -related peptide fragments or analogs
For females: changes in hormone replacement therapy within 3 months are excluded. Stable ( ≥ 3 
months) hormone replacement therapy is acceptable.
6 months –fluoride tablets, oral bisphosphonates, methotrexate, grow th hormone, digoxin, 
raloxifene or similar selective estrogen receptor modulators (SERMs)
12 months –intravenous bisphosphonates, drug or alcohol abuse, as determined by the 
investigator
8.Confirmed systolic blood pressure (BP) >139mmHg or <89mmHg, and diastolic BP >89mmHg or 
<49mmHg.
9.Twelve-lead E CG demonstrating measure of time between the start of the Q wave and the end of the T w ave 
using Fridericia’s formula in an electrocardiogram (QTcF) >450msec at screening.  If QTcF exceeds 
450m sec, the ECG should be repeated 2 more times and the average of the 3 QTcF values should be used to 
determine the subject’s eligibility.
10.Positive screen for drugs of abuse at screening or drugs of abuse or alcohol on Day -1.
11.Male subjects who consume more than 21 units of alcohol per w eek or 3 units per day.  Female s ubjects 
who consume more than 14 units of alcohol per week or 2 units per day.  (1 alcohol unit=1 beer or 1 w ine 
(5oz/150 mL) or 1 liquor (1.5oz/40 mL) or 0.75 oz alcohol).
12.Positive human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), o r hepatitis C virus 
(HCV) antibody screen.
Shire CONFIDENTIAL Page 17
SHP634 -102 Protocol
Natpara 29Jan 2017
13.Use of tobacco in any form (eg, smoking or chewing) or other nicotine -containing products in any form 
(eg, gum, patch).  Ex -users must report that they have stopped using tobacco for at least 30 days prior to 
receiving the first dose of investigational product.
14.Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine 
withdrawal headaches.  (1 caffeine unit is contained in the follow ing items: one 6 oz (180 mL) cup of 
coffee, two 12 oz (360 mL) cans of cola, one 12 oz cup of tea, three 1 oz (85 g) chocolate bars.  
Decaffeinated coffee, tea, or cola are not considered to contain caffeine).
15.Prior screen failure, randomization, participation, or enrollment in this study or prior e xposure to any 
exogenous PTH, PTH fragments or analogs.
16.Current use of any medication (including over -the-counter, herbal, or homeopathic preparations; with the 
exception of hormonal replacement therapy or hormonal contraceptives and occasional use of ibup rofen 
and acetaminophen). Current use is defined as use within 14 days of the first dose of investigational 
product.
17.History of abnormalities of calcium homeostasis including hyperparathyroidism, hypoparathyroidism, 
hyperthyroidism, osteoporosis, Cushing’s syndrome, hypercalcemia, hypocalcemia, or any other calcium 
disorder.
Maximum duration of subject involvem ent in the study:
Subjects will be screened within 28 days prior to the dose of the investigational product.
 There w ill be 1 treatment period for th e non -Hispanic, Caucasian group consisting of one SC 
injection of rhPTH(1 -84) and 1 treatment period for the subjects of Japanese descent consisting of 
3, randomized (only tw o of the doses w ill be randomized) , SC injections of rhPTH(1 -84); each 
subject w ill check in to the unit on Day -1 and remain in the unit until discharge (Day 2 for the 
non-Hispanic, Caucasian subjects and Day 8 for the subjects of Japanese descent). Non -Hispanic, 
Caucasian subjects will be dosed on Day 1 only and w ill spend 3 days and 2 nights in the unit. 
Volunteers of Japanese descent will be dosed on Days 1, 4 and 7 and w ill spend 9 days and 8 
nights in the unit.
 There w ill be a follow -up clinic visit 30 ± 2 days after the last dose of the investigational product 
for each subject.
 The total number of nights non -Hispanic, Caucasian subjects will be expected to stay at the 
clinical research center (CRC) is 2. The total number of nights subjects of Japanese descent w ill be 
expected to stay at the clinical research center (CRC) is 8. The maximal total duration of study 
participation for any subject is 68 days, if the maximum screening, treatment and follow -up visit 
durations are used.
Endpoints and statistical analysis:
No formal calculations were performed to determine sample size for th is study. The sample size is based on 
feasibility and is similar to that of comparable studies.
Subject Populations:
 The safety population includes subjects who have received at least 1 dose of rhPTH(1 -84).
 The PK population consists of subjects who receiv e at least 1 dose of rhPTH(1 -84) and have at 
least 1 evaluable post dose PK concentration value.
 The PD population consists of subjects who receive at least 1 dose of rhPTH(1 -84) and have at 
least 1 evaluable post dose PD concentration value.
Pharm acokinet ic Endpoint(s):
A PK evaluation of PTH concentrations and baseline -adjusted PTH concentrations will be performed following the 
administration of rhPTH(1 -84) on Day 1 for non -Hispanic, Caucasian subjects and Days 1, 4 and 7 for subjects of 
Japanese descent.
Shire CONFIDENTIAL Page 18
SHP634 -102 Protocol
Natpara 29Jan 2017
Pharm acokinetic param eters will be calculated from original and baseline -adjusted plasma concentration -time data 
using non -compartmental methods and all calculations will be based on actual sampling times. Baseline is defined as 
the average Day 1 pre -dose concentration for all subjects (and the Day 4 and Day 7 average pre- dose concentration 
for the subjects of Japanese descent for those respective dosing intervals ). PK parameters will be estimated based on 
non
-compartmental analysis and will include, but n ot be limited to, the following:
Cmax: Maximum concentration occurring at t max
tmax: Time of maximum observed concentration sampled during a dosing interval
AUC last: Area under the curve from the time of dosing to the last measurable concentration
  z: First order rate constant associated w ith the terminal (log linear) portion of the curve
t½: Term inal half -life
CL/F: Apparent clearance
Vd z/F: Apparent volume of distribution
Non-body  weight adjusted and b ody w eight -adjusted AUC last, Cmax, CL/F, and Vd z/F will be estimated. In addition, 
dose- norm alized baseline -adjusted AUClast and Cmax will be calculated. 
Statistical Methodology for Pharm acokinetic Endpoint(s) :
Individual concentrations (original and baseline- adjusted) and PK parameters (original, baselin e-adjusted, body 
weight -adjusted, and dose- normalized -baseline- adjusted) of rhPTH(1 -84) w ill be listed and summarized with 
descriptive statistics (number, arithmetic mean, standard deviation [SD], coefficient of variation [CV%], median, 
minimum, maximum, g eometric mean, and %CV of geometric mean. The 95% confidence intervals of the geometric 
means of PK parameters will be presented as well. Figures of individual and mean (±SD) concentration -time profiles 
of the original and baseline -adjusted plasma rhPTH(1 -84) w ill be generated on linear and semi -log scales. The mean 
plots w ill be generated by overlaying the Japanese cohort and Non -Japanese cohort. Figures of baseline- adjusted PK 
parameters and dose- norm alized baseline -adjusted PK parameters vs dose in Japan ese subjects will be generated. 
Box-Whisker plots for selected PK parameter will be generated w ith Japanese cohort and Non -Japanese side by side. 
Forest plots of geometric mean ratios for selected PK parameters betw een Japanese cohort vs Non -Japanese cohor t 
will be generated.
Dose proportionality of PKparam eters will also be examined for the Japanese subjects. Dose proportionality will be 
assessed for Cmax and AUC (AUC0 -last) using the pow er model. The pow er model assumes a linear relationship 
betw een the natural log transformed parameter and the natural log transformed dose.
ln (Parameter) = α + β × ln (Dose) + Random error
Where α is the intercept, β is the slope, and Random error is a random residual error. Dose proportionality implies 
that slope = 1 and will be assessed by estimating mean slope w ith the corresponding two sided 90% confidence 
interval (CI) from the pow er model.
In order to compare the PKs of rhPTH(1 -84) betw een subjects of Japanese descent and matched non -Hispanic, 
Caucasian subjects, the differences of log -transformed PKparam eters from the rhPTH 100ug dose will be examined 
betw een groups using an analysis of variance model. The geometric mean ratio and its 90% confidence interval (CI) 
will be provided from the model. Baseline -adjusted PK parameters will be the primary PK endpoints, and other PK 
parameters will be the secondary PK endpoints. In addition, the difference of log -transformed dose- norm alized 
baseline -adjusted AUClast and Cmax will be examined between the Japanese cohort estimated at the 50ug dose and 
the Non -Japanese cohort estimated at 100ug dose, as w ell as betw een the Japanese cohort estimated at the 25ug dose 
and the Non -Japanese cohort estimated at 100ug dose using an analysis of variance model. The geometric mean 
ratio an d its 90% CI w ill be provided from the model.
Pharm acodynamic Endpoint(s):
Pharm acody namic parameters w ill be computed from individual post dose values of serum calcium (uncorrected and 
Shire CONFIDENTIAL Page 19
SHP634 -102 Protocol
Natpara 29Jan 2017
corrected for serum albumin levels and both unadjusted and baseline -adjusted) and phosphate using non -
compartmental methods. Pharmacodynamic parameters will be estimated based on both original and baseline -
adjusted values of serum calcium and phosphate. The calcium -phosphate product w ill be computed. Baseline is 
defined as t he pre- dose value on Day 1 for all subjects and, additionally, also on Day 4 and Day 7 for the subjects of 
Japanese descent. All calculations will be based on actual sampling times. Pharmacodynamic parameters will be 
estimated based on non -compartm ental an alyses and will include, but not be limited to, the following:
 AUC last:Area under the curve from the time of dosing to the last measurable concentration
 tmax: Time of maximum observed concentration sampled during a dosing interval
 Emax: Maximum effect
 TE max:Time to maximum effect
Statistical Methodology for Pharm acodynamic Endpoint(s) :
Individual values (original and baseline- adjusted) and PD parameters (original and baseline- adjusted) of serum total 
calcium, albumin -corrected calcium, phosphate and the c alcium -phosphate (albumin -corrected calcium) product will 
be summarized with descriptive statistics (number, arithmetic mean, SD, CV%, median, minimum, maximum, 
geometric mean, and geometric CV%). Figures of individual and mean (±SD) concentration -time pro files of the 
original and baseline -adjusted PD markers, serum calcium (total and corrected for serum albumin) and phosphate, 
will be generated. Mean plots will be overlaid for the Japanese cohort and the Non -Japanese cohort. Box -Whisker 
plots for selected PD parameters w ill be prepared w ith the Japanese cohort and Non -Japanese cohort side by side.
Safety Endpoint(s) :
Clinical laboratory tests, vital signs, and ECG findings will be summarized by treatment group and visit as indicated 
below :
 Number, severity, seriousness and causality of treatment -emergent adverse e vents
 Anti-PTH antibodies
 Changes in vital signs , ECGs, and clinical laboratory results (hematology, chemistry, and 
urinalysis) from baseline to post baseline time points
Statistical Methodology for Safety Endpoint(s)
Safety data, including TEAEs, laboratory tests, anti -PTH antibodies, and vital signs, will be summarized. 
Descriptive statistics will be calculated for quantitative safety data as well as for the difference from baseline, if 
applicable. Frequency counts will be compiled for classification of qualitative safety data. Direct safety comparisons 
betw een the two ethnic groups w ill be presented from the rhPTH(1 -84) 100µg dosing data. All other safety data 
from the 25µg and 50µg in the subjects of Japanese descent will be summarized and listed. Treatment- emergent AEs 
(TEAEs) are defined as AEs with start dates betw een the time of the first exposure to study drug and the last dose of 
the study drug.
Shire CONFIDENTIAL Page 20
SHP634 -102 Protocol
Natpara 29Jan 2017
STUDY  SCHEDULE(S)
Table 1 Schedule of Assessments
Visit ScreeningPredose 
assessmentsTreatment Period Follow -uph
Study Day –28 to - 02 -1 1 2 3 4 5 6 7 8
Informed consent X
Inclusion/exclusion 
criteriaX X
Demography and 
medical/medication 
historyX
Physical examinationaX X X
Vital signs (BP, 
temperature and pulse)a, b, 
gX X X X XjXjXjXjX
Height and weightcX X
Serum PTH X X
Electrocardiogram (12-
lead)a, g X X X XjXjXjXjX
Biochemistry, 
hematology, and 
urinalysisaX X X XjXjXjX
HIV, HBsAg, and HCV 
antibodiesX
Pregnancy test (females X X X XjX
Shire CONFIDENTIAL Page 21
SHP634 -102 Protocol
Natpara 29Jan 2017
Table 1 Schedule of Assessments
Visit ScreeningPredose 
assessmentsTreatment Period Follow -uph
Study Day –28 to - 02 -1 1 2 3 4 5 6 7 8
only)a, d
Urine drug and alcohol 
screeninge X X
Randomization X j
Investigational drug 
administrati onk X XjXj
Pharmacodynamic blood 
samplingf, g X X XjXjXjXj
Anti- PTH antibody 
samplingg X Xa
Pharmacokinetic blood 
samplingg X X XjXjXjXj
Check- in to the CRC X
Discharge from the CRC XiXj
Adverse events/serious 
adverse eventsa X X X X X jX jX jX jX jX jXl
Concomitant medicationaX X X X XjXjXjX jX jX jX
BP=blood pressure; CRC=clinical research center; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human im munodeficiency virus; PTH=parathyroid hormone
aIn the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete thes e assessments.
b Vital signs will be obtained while subject is supine on study days noted. Temperature will only be taken at screening and predose on Day 1.
cHeight will be recorded at the screening visit only.
dFSH (follicle stimulating hormone) is required at screening for all females. Serum β -hCG testing at timepoints indicated for all female subjects.
e Drugs of abuse at screening and drugs of abuse and alcohol on Day -1.
f  Pharmacodynamic blood sampling assessments will include serum calcium and phosphate.
Shire CONFIDENTIAL Page 22
SHP634 -102 Protocol
Natpara 29Jan 2017
Table 1 Schedule of Assessments
Visit ScreeningPredose 
assessmentsTreatment Period Follow -uph
Study Day –28 to - 02 -1 1 2 3 4 5 6 7 8
gSeeTable 2andTable 3 fordetailed collection time points.
h There will be a follow -up visit approximately 30 ±2 days following the last dose of investigational product.
iNon-Hispanic, Caucasian subjects only.
jSubjects of Japanese descent only.
kThere must be a minimum washout period of 72 hours (maximum 73 hours) from do se to dose for the volunteers of Japanese descent.
lSAEs will be followed to resolution (see Section 7.1.3 )
Shire CONFIDENTIAL Page 23
SHP634 -102 Protocol
Natpara 29Jan 2017
Table 2 Detailed Schedule of Assessments (non -Hispanic, Caucasian Subjects)
Study Day Day 1Day
2
Hour (relative to dosing 
time)Pre
Dose 
1Pre
Dose 
20 10m 20m 30m 45m 1h 1.25h 1.5h 2h 2.5h 3h 4h 6h 8h 12h 16h 24h
Physical examinationaX
Vital signs (BP, 
temperature and pulse)a,b XeX X X X
Electrocardiogram 
(12-lead)a,c XeX
Biochemistry, hematology, 
and urinalysisa XeX
Serum β -hCG  Pregnancy 
test (females only)a X
Investigational drug 
administrationX
Pharmacodynamic blood 
samplingd XeX X X X
Anti-PTH antibody 
samplingXe
Pharmacokinetic blood 
samplingXfXeX X X X X X X X X X X X X X X X
BP=blood pressure; ECG=electrocardiogram; PK=pharmacokinetic, PTH=parathyroid hormone
aIn the event a subject is prematurely discontinue d from the study or withdraws, every attempt should be made to complete these assessments.
bVital signs will be obtained while subject is supine at times noted. Temperature only to be obtained at screening and at pred ose on Day 1.
cElectrocardiograms will be performed in triplicate at each timepoint. 
d Pharmacodynamic blood sampling assessments will include serum calcium and phosphate and must be drawn before PK samples at th e same timepoint.
eThese assessments should be performed within 30 minutes prio r to dose administration.
fThese assessments should be performed within 90 (±30) minutes prior to dose administration.
Shire CONFIDENTIAL Page 24
SHP634 -102 Protocol
Natpara 29Jan 2017
Table 3 Detailed Schedule of Assessments (Subjects of Japanese Descent)
Study Day Days 1, 4 and 7Days
2, 5 
and 
8
Hour (relative to dosing 
time)Pre-
dose 
1Pre-
dose
20 10m 20m 30m 45m 1h 1.25h 1.5h 2h 2.5h 3h 4h 6h 8h 12h 16h 24h
Physical examinationaXh
Vital signs (BP, 
temperature and pulse)a,b XeX X X X
Electrocardiogram
(12-lead)a,c XeX
Biochemistry, hematology, 
and urinalysisa XeX
Serum β -hCG  Pregnancy 
test (females only)a Xh
Investigational drug 
administrationX
Pharmacodynamic blood 
samplingd XeX X X X
Anti- PTH antibody 
samplingXe
Pharmacokinetic blood 
samp lingXfXeX X X X X X X X X X X X X X X X
BP=blood pressure; ECG=electrocardiogram; PK=pharmacokinetic, PTH=parathyroid hormone
aIn the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete the se assessments.
bVital signs will be obtained while subject is supine at times noted. Temperature only to be obtained at screening and at pred ose on Day 1.
cElectrocardiograms will be performed in triplicate at each timepoint.
d Pharmacodynamic blood sam pling assessments will include serum calcium and phosphate and must be drawn before PK samples at the same timepoint.
eThese assessments should be performed within 30 minutes prior to dose administration.
fThese assessments should be performed within 90 (±30) minutes prior to dose administration.
hSerum β -hCG  Pregnancy test (females only) and physical exam on Day 8 at discharge only.
Shire CONFIDENTIAL Page 25
SHP634 -102 Protocol
Natpara 29Jan 2017
1. BACKGROUND INFORMATI ON
Hypoparathy roidism is a rare disorder characterized by  hypocalcemia in the presence of 
inappropriatel y low or undetectable levels of circulat ing parath yroid hormone (PTH) 
(Avioli 1974; Haussler and Cordy  1982; Shoback 2008 ). The most frequent cause of 
hypoparathy roidism is resection of, or damage to, parathy roid glands during neck surgery  (eg, 
thyroidectomy ), although multiple other genetic, metabolic and congenital etiologies exist. 
Hypoparathy roidism occurs in about 0.9% to 6.6% of thy roidec tomies, with higher rates 
associated with more complicated interventions ( Shoback 2008; Thomusch et al. 2003 ; Zarnegar 
et al. 2003; Page and Strunski 2007). I n 1 y ear spanning 2007 - 2008 ( Powers et al. 2013) the 
incidence of chronic h ypoparath yroidism ( ≥6 months) was said to be approximately  60,000 
subjects in the United States, which rises to approximately  117,000 if the transient 
hypoparathy roid population is included ( ≤6 months). The same authors suggest that, of those 
117,000 transient hy poparathy roid subjects, about 5% will become chronic
.
Parathy roid hormone is an 84 -amino acid protein that is secreted b y the parathyroid glands. PTH 
has a variety  of important phy siological functions that are outlined below to explain the effects 
of absent or deficient PTH levels. Parath yroid hormone funct ions to help regulate bone 
metabolism and serum levels of calcium and phosphate. In general, if serum calcium 
concentrations decrease, the parath yroid glands consequently increase PTH secretion, and, if 
serum calcium concentrations increase, the parathy roid glands consequently  reduce PTH 
secretion. The parathy roid glands sense the level of extracellular calcium at the surface of the 
parath yroid cell and adjust the sy nthesis and secretion of PTH accordingl y. The relationship 
between ionized extracellular cal cium and PTH secretion is a steep sigmoidal curve where small 
variations in calcium level lead to significant changes in PTH secretion. Calcium sensing is 
initiated by  the binding of calcium to a calcium sensing receptor (CaSR) that is present at high 
levels on the plasma membrane of the parath yroid cells. The CaSR, a member of the G -protein 
coupled receptor superfamily , is activated by  calcium binding to it that, in turn, induces 
intracellular signals and, through largel y unknown mechanisms, regulates the synthesis and 
secretion of PTH. The net phy siological effects are an increase in circulating PTH levels when 
the extracellular calcium decreases and a decrease in PTH levels when the extracellular calcium 
increases ( Bilezikian et al. 2011 ).
Acute s ymptoms of hy poparathy roidism, linked mainly  to the hy pocalcemia, are generall y 
reversible. The key  symptoms associated with hy pocalcemia involve mainly  the neuromuscular 
system: numbness, paresthesias, twitching, and tetany . More serious and potentially  life 
threatening effects of h ypocalcemia such as seizures, cardiac arrh ythmias, cardiom yopath y and 
laryngeal spasm are also recognized in h ypoparathyr oidism ( Behaghel and Donal 2011 ). Other 
symptomatology  includes difficulty  in concentrating described b y man y subjects as “brain fog” 
(Bilezikian et al. 2011 ). Hy poparathy roidism has also been linked to effects on mood and 
ideation ( Arlt et al. 2002 ; Velasco et al. 1999 ).
The kidney s are especially  vulnerable in subjects with hy poparathy roidism. Circulating PTH 
promotes renal calcium reabsorption, especiall y at the level of the distal convoluted tubule 
(Blaine et al. 2015 ). This additional fraction of calcium is instead excreted through the kidney s 
(Shoback 2008), leading to hy percalciuria which, together with a high- calcium -phosphate 
Shire CONFIDENTIAL Page 26
SHP634 -102 Protocol
Natpara 29Jan 2017
product, can potentially  can lead to nephrocalcinosis and kidney  stones and, ultimately , to renal 
impairment (Blaine et al. 2015 ).
For further details see the current rhPTH(1 -84) investigator brochure.
1.1 Indication and Current Treatment Options 
Prior to 2015, in the absence of an approved PTH replacement therapy , management of 
hypoparathy roidism consisted of supplemental oral calcium and active vitamin D in 
pharmacological doses sufficient to maintain the serum calcium level without the disabling 
symptoms of hypocalcemia. I n order to improve the absorption of calcium from the 
gastrointestinal tract, pharmacological supplementation with active forms of vitamin D (eg, 
1,25- dihydroxyvitamin D 3 [1,25(OH) 2D3], calcitriol, 1,25 -dihydroxycholecalciferol or α -calcidol 
[1(OH)D 3]) is also required. Since PTH also functions in the kidney  to stimulate the conversion 
of 25(OH)D 3, the major circulating form of vitamin D, to the active vitamin D hormone 
(1,25[OH] 2D3), the relative lack of circulating PTH results in a reduction of the production of 
active vitamin D. Thus, exogenous active vitamin D overcomes the s ynthetic block in 
endogenous production of the active vitamin D hormone in hy poparathy roidism. Together, 
supp
lemental oral calcium and active vitamin D have formed the mainstay  of current treatment 
of subjects with hy poparathy roidism. As noted above, the additional calcium load that results 
from supplementation with exogenous calcium and active vitamin D contribu tes to the 
hypercalciuria and renal risks often noted in patients with hy poparathy roidism.
In an effort to limit the extent and effect of h ypercalciuria, thiazide diuretics can be helpful since 
they promote renal calcium reabsorption. However, thiazides ar e associated with their own 
adverse events including hy pokalemia and, more importantly , have no proven long- term effect to 
reduce h ypercalciuria or kidney damage or improve the safety profile in this patient population 
(Shoback 2008). Although an accepted adjunct to the use of calcium and active vitamin D in 
hypoparathy roidism, thiazides are prescribed to only  a minorit y of h ypoparathy roid patient s.
The investigational product (rhPTH[1- 84]) is a recombinant human PTH that is identical in 
structure to endogenous human PTH, a single -chain poly peptide consisting of 84 amino acid 
residues and is manufactured using a strain of Escherichia coli modified by recombinant DNA 
technology . rhPTH(1- 84) was approved for marketing in the United States on 23 January  2015 
under the brand name NATPARA®as a once -daily injectable dose as an adjunct to calcium and 
vitamin D to control hy pocalcemia in patients with hy poparathy roidism.
1.2 Product Background
1.2.1 Preclinical Information
A total of 46 in vivo studies in mouse, rat, rabbit, dog, and rhesus and cy nomolgus monkey s 
have evaluated the PKs, PDs 
and toxicology  of rhPTH(1 -84) at doses ranging from 0.1 to 10,000 
μg/kg given as single doses or as dail y doses for up to 2 y ears. In the vast majority  of studies, 
rhPTH(1 -84) was administered b y subcutaneous (SC) injection, the intended route of 
administr ation of rhPTH(1 -84) in humans. A total of 7 in vitro pharmacology  and toxicology  
studies have been performed.
Shire CONFIDENTIAL Page 27
SHP634 -102 Protocol
Natpara 29Jan 2017
In male and female rats, the administration of PTH was associated with an increase in the 
incidence of osteosarcoma. These data were interpreted as an increased risk for osteosarcoma in 
the clinic. Therefore, administration of rhPTH(1-84) should be avoided in subjects who are 
considered to be at increased risk for osteosarcoma (including those with Paget’s disease of bone 
or unexplained elevations of alkaline phosphatase, subjects with hereditary disorders 
predisposing to osteosarcoma or subjects with a history of prior external beam or implant 
radiation therap y involving the skeleton). Currently available results from animal reproductive 
toxicology studies suggest that rhPTH(1- 84) is not associated with significant fetal or neonatal 
toxicity ; however the safety  of rhPTH(1- 84) in pregnant or nursing women is not established.
For full details see the rhPTH(1- 84) investigator brochure.
1.2.2 Clinical Information
Few studies of PTH use have been performed in the setting of h ypoparath yroidism. Study  
CL1-11- 040 (REPL ACE) was a double -blind, placebo controlled stud y of once dail y (QD) 
administration of 50μg to 100μg of rhPTH(1 -84) which resulted in 54.8% of the r hPTH(1- 84) 
subjects meeting a 3 -tiered primary  endpoint vs 2.5% of the placebo subjects (p<0.001). 
Long -term, open-label studies have supported these findings with subjects maintaining the 
physiologic benefit derived from rhPTH(1- 84) treatment. One study , PAR -C10- 008 (RACE), is 
ongoing with subjects receiving treatment for more than 5 years.
In clinical trials, rhPTH(1- 84) significantl y reduced the calcium -phosphate product. In these 
studies hy percalciuria was defined as an excretion of calcium in the urine greater than 300mg per 
24 hours. Data from the REPL ACE Study  and the long -term open label study , RACE, show that 
rhPTH(1 -84) has a calcium -sparing effect, consistent with the reduction of calcium excretion 
seen in a previous PK/PD study  (C09- 002) of singl e dose administration of rhPTH(1 -84) in 
patients with hy poparathy roidism in comparison with calcitriol administration.
The Phase 3 clinical study , REPLACE, was the largest, randomized, placebo controlled clinical 
study  conducted in hy poparathy roidism popul ation and was the pivotal study  demonstrating that 
rhPTH(1 -84) is effective in maintaining serum calcium levels and enabling significant decreases 
in active vitamin D and oral calcium doses. REPLACE also established the rhPTH(1 -84) dose 
and dose titration and evaluated the ph ysiologic effects of PTH replacement on serum calcium, 
serum phosphate, urinary calcium excretion and bone turnover markers. Eight y-four subjects 
were evaluated in the active treatment group and 40 subjects received placebo. Subjects re ceived 
at a flexible dose range of 50 to 100μg SC in the thigh once dail y for 6 months. The study met 
the primary  efficacy  triple endpoint, with a statistically  higher responder rate (54.8%) versus 
placebo (2.5%). To meet the primary  endpoint a subject had to fulfill all 3 conditions as follows: 
a 50% or greater reduction in oral calcium requirement, a 50% or greater reduction in active 
vitamin D therap y and an albumin corrected serum calcium (ACSC) concentration that was 
maintained within a range of 7.5 to 10.6 mg/dL.
A review of safety  data across the hy poparathry odism program indicated that rhPTH(1- 84) 
administered in the dose range of 25 to 100μg SC QD is safe for use for the treatment of 
hypoparathy roidism. Very  common adverse reactions (ie, reported in at least 1 i n every  10 
subjects) included h ypocalcemia, h ypercalcemia, headaches, diarrhea, vomiting, and 
Shire CONFIDENTIAL Page 28
SHP634 -102 Protocol
Natpara 29Jan 2017
hypercalciuria. Common adverse reactions (ie, reported in at least 1 in every  100 subjects, but 
less than 1 in every  10 subjects) included hy pomagnesemia, anxiety symptoms, palpitations, 
flushing, coughing and associated s ymptoms, neck pain, pollakiuria, chest pain, thirst, blood 
25-hydroxy cholecalciferol decreased, and blood alkaline phosphatase increased.
There was no suggestion that rhPTH(1- 84) causes drug -induc ed liver injury in humans. There 
were no renal -related adverse events (AEs) or abnormalities in renal function tests or urinaly sis 
tests in clinical studies apart from changes expected from the mechanism of action of rhPTH(1 -
84). Despite significant increases in total serum calcium levels and improved calcium 
homeostasis, treatment with rhPTH(1- 84) did not result in worsening of hy percalciuria.
Potential risks include those effects which are extensions of the pharmacologic actions of PTH 
including h ypercalc emia. Post -treatment hy pocalcemia following the abrupt withdrawal of 
rhPTH(1 -84) can be particularl y problematic. Following sustained withdrawal of rhPTH(1 -84), 
serum calcium levels must be carefully monitored with reinstatement of appropriate dosages of 
oral calcium and active vitamin D. No on- treatment events of h ypocalcemia occurred following 
incidental missed doses of rhPTH(1 -84) during any  of the clinical studies; patients should be 
advised, however, to take their rhPTH(1 -84) dose as soon possible foll owing a missed dose and 
to take oral calcium.
The investigational product (rhPTH[1
-84]) has been developed for the treatment of 
hypoparathy roidism. In the United States the drug is currentl y marketed under the brand name 
NATPARA as a once a day injectable treatment, indicated as an adjunct to calcium and vitamin D 
to control hy pocalcemia in patients with hy poparathy roidism. However, because of the potential 
risk of osteosarcoma, N ATPARA is recommended only  for patients who cannot be well -controlled 
on calci um supplements and active forms of vitamin D alone.
Alway s refer to the latest version of the rhPTH(1 -84) investigator’s brochure for the overall 
risk/benefit assessment and the most accurate and current information regarding the drug 
metabolism, PKs, effi cacy, and safet y of rhPTH(1 -84).
1.3 Risk/Benefit and Ethical Assessment
There is no anticipated benefit from taking part in this study .
Risks for subject exposure to rhPTH(1 -84) are listed in the current investigator brochure and 
include, but are not limited to, the following:
Osteosarcoma: In male and female rats, parathyroid hormone caused an increase in the 
incidence of osteosarcoma (a malignant bone tumor). The occurrence of osteosarcoma was 
dependent on parath yroid hormone dose and treatment duration. This effect was observ ed at 
parath yroid hormone exposure levels ranging from 3 to 71 times the exposure levels in 
humans receiving a 100μg dose of rhPTH(1 -84). These data could not exclude a risk to 
humans. Because of a potential risk of osteosarcoma, it is recommended to use r hPTH(1- 84) 
only in subjects with hy poparathy roidism who cannot be well- controlled on calcium and 
active forms of vitamin D alone and for whom the potential benefits are considered to 
Shire CONFIDENTIAL Page 29
SHP634 -102 Protocol
Natpara 29Jan 2017
outweigh this potential risk. Use of rhPTH(1 -84) is to be avoided in subj ects who are at 
increased baseline risk for osteosarcoma such as subjects with Paget’s disease of bone or 
unexplained elevations of alkaline phosphatase, pediatric and young adult subjects with open 
epiphy ses, subjects with hereditary  disorders predisposin g to osteosarcoma or subjects with a 
prior history  of external beam or implant radiation therapy  involving the skeleton.
Hypercalcemia during initiation of rhPTH(1 -84) administration: I n previous efficacy  and 
safet y studies in hypoparathyroidism, 29 of 121 (24.0%) rhPTH(1- 84)-treated subjects 
experienced an on -treatment event of h ypercalcemia. Monitoring of serum calcium during 
the treatment process can mitigate the risk, along with appropriate medical treatment.
Hypocalcemia with abrupt withdrawal of rhPT H(1-84) therap y: In previous efficacy  and 
safet y studies in hypoparathyroidism, 24 of 121 (19.8%) subjects experienced a post -
treatment event of h ypocalcemia. Monitoring of serum calcium during the treatment process 
and after withdrawal can mitigate the ri sk, along with appropriate medical treatment.
The safet y of rhPTH(1 -84) in pregnant or nursing women has not been established. 
Pregnancy  tests will be performed on all females on 2 occasions prior to entering the 
treatment phase of the study , and at discha rge after treatment and at follow -up. Both men and 
women must agree to adequate contraception methods (see Section 4.4) before taking part in 
the study .
Shire CONFIDENTIAL Page 30
SHP634 -102 Protocol
Natpara 29Jan 2017
2. STUDY OBJECTIVES AND PURPOSE
2.1 Rationale for the Study
Recombinant human PTH (rhPTH[1- 84]) is approved for use in the United States (US) as an 
adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. As a 
once -daily SC injection for hy poparathy roidism, it has been shown to provide a 24- hour 
sustained increase in serum cal cium. Administration of rhPTH(1 -84) resulted in dose -related 
increases in total serum calcium levels, with maximum mean increases (approximately  0.125 to 
0.175 mmol/L) observed 12 hours after dosing. Serum calcium levels did not return to baseline 
levels b y 24 hours. This sustained increase may  explain the reduction in the observed dail y 
amounts of calcium and active vitamin D that were taken in the placebo -controlled trial.
Other clinical studies have reported experience with twice -daily use of a fragment of PTH 
(PTH[1 -34]) injected SC in the setting of adult and pediatric subjects with hypoparath yroidism 
(Winer et al. 1998 ; Winer et al. 2003 ; Winer et al. 2008). In this setting, P TH(1 -34) maintained 
eucalcemia and reduced urinary  calcium excretion. I n these studies, a comparison with calcitriol 
showed that either twice -daily  PTH(1 -34) or twice -daily  calcitriol each maintained similar serum 
calcium levels, although urinary  calcium e xcretion was lower in the PTH(1-34)- treated subjects.
Shire intends to develop rhPTH(1 -84) for use in Japan. The Japanese regulatory  agencies, 
Pharmaceuticals Medical Devices Agency  (PMDA) and the Ministry  of Health, Labor and 
Welfare (MHLW), require evide nce that current data in non -Japanese subjects can be 
extrapolated to the Japanese population, since Japanese patients may  require different doses of 
medication of some drug classes. 
To satisfy  the PMDA and MHL W requirements, sponsors will provide data to support doses for 
a later stud y in Japanese subjects. The present study to compare PKand PDprofiles and safet y 
and tolerability  in Japanese and (non-Hispanic) Non- Hispanic, Caucasian healthy  volunteer 
subjects is designed for this reason. In addition, t
his study  will also assess the PK dose -
proportionality  of rhPTH(1-84) using three, randomized, single, SC doses of 25µg, 50µg and 
100µg in health y volunteers of Japanese descent.
2.2 Study Objectives
2.2.1 Primary Objective
To compare the PK profile of recombinant h uman parathy roid hormone (rhPTH[1- 84]), 
administered as a single subcutaneous (SC) do se of 100μg, between healthy adult volunteer 
subjects of Japanese descent and matched, non -Hispanic, healthy , adult Caucasian subjects.
2.2.2 Secondary Objectives
To assess the dose proportionality  of the PKs of rhPTH(1- 84) in health y adult volunteer 
subjects of Japanese descent when expose d to single SC doses of rhPTH(1- 84) at 25µg, 
50µg ,
and 100µg.
Shire CONFIDENTIAL Page 31
SHP634 -102 Protocol
Natpara 29Jan 2017
To compare the PD profile (including measurement of serum calcium and phosphate levels) 
of a 100μg SC injection of rhPTH(1 -84) in healthy  adult volunteer subjects o f Japanese 
descent and matched, non- Hispanic, healthy , adult Caucasian, subjects.
To assess the PD profile (including measurement of serum calcium and phosphate levels) of 
a 25μg and 50µg SC injection of rhPTH(1 -84) in healthy  adult volunteer subjects of J apanese 
descent.
To assess the safet y and tolerability of single SC doses of 25µg, 50 µg and 100µg of 
rhPTH(1 -84) in healthy  adult volunteer subjects of Japanese descent.
To evaluate the safet y and tolerability  of a 100µg SC injection of rhPTH(1- 84) in mat ched, 
non-Hispanic, healthy , adult volunteer Caucasian subjects.
Shire CONFIDENTIAL Page 32
SHP634 -102 Protocol
Natpara 29Jan 2017
3. STUDY DESIGN
3.1 Study Design and Flow Chart
This is a P hase 1, open-label, randomized, cross- over, single -center study  to evaluate the PK and 
PD profiles and safet y and tolerability of rhPTH(1 -84) administered in healthy  adult volunteer 
subjects of Japanese descent and matched non -Hispanic, Caucasian healthy  adult volunteer 
subjects. The non -Hispanic, Caucasian volunteers will receive a single dose of 100µg rhPTH(1-
84). The Japanese subjects wil l receive 3 single doses of rhPTH(1- 84). On Day 1 the subjects of 
Japanese descent will receive a single SC injection of 100µg. On Days 4 and 7 the subjects of 
Japanese descent will be randomized to receive a single SC injection of either 25µg or 50µg. 
such that all of these subjects are exposed to the 3dose strengths over a 7 day  period to further 
characterize the PK profile in that group. A total of 24 subjects will be enrolled: 12 non -
Hispanic, Caucasian subjects and 12 subjects of Japanese descent (1:1 male: female). Non -
Hispanic, Caucasian subjects will be matched to Japanese subjects based on sex, age ( ±5 years), 
weight ( ±10%), and body mass index ( ±15%). 
All subjects will receive a single dose of 100μg rhPTH(1- 84) administered by  SC injection in the 
mid-thigh with the Haselmeier injector pen on Day 1. In addition, the subjects of Japanese 
descent will also receive single dose injections of 25µg and 50µg rh PTH(1 -84) administered b y 
SC injection in the mid- thigh to characterize the PK profile over a range of doses. There will be a 
minimum of 72 hours (maximum 73 hours washout from single dose to single dose for the 
volunteers of Japanese descent. The stud y duration will comprise of a 28 -day screening period, 1 
treatment period for the non- Hispanic, Caucasian group (Day s 1 and 2); 1 treatment period for 
the volunteers of Japanese descent (Day s 1
-8), and a follow -up visit (30±2 day s) after the last 
dose of inves tigation drug is administered for each subject. The total number of nights subjects 
will be expected to stay at the clinical research center (CRC) is 2 for the non -Hispanic, 
Caucasian group and 8 for the volunteers of Japanese descent. The maximal total duration of 
study  participation for a non -Hispanic, Caucasian subject is 62 day s and 68 day s for the 
volunteers of Japanese descent, if the maximum screening, treatment and follow -up visit 
durations are used.
Screening will occur within 28 day s of the first 
dose. Subjects will be admitted to the CRC on 
Day -1.
Treatment Period:
On Day  1, all study  subjects will receive rhPTH(1-84) as a single 100μg SC injection in the 
mid-thigh.
On Day  4, and Day  7, all subjects of Japanese descent will receive rhPTH(1 -84) as a single 
SC injection in the mid
-thigh of either 25µg or 50µg depending upon randomization 
assignment. Administration of rhPTH(1 -84) in subjects of Japanese descent in the mid- thigh 
should be randomized locally  so that an equal number of subjects receive the first dose in the 
right thigh and an equal number in the left thigh. Subsequent doses should be administered in 
the opposing thigh to the last dose.
Shire CONFIDENTIAL Page 33
SHP634 -102 Protocol
Natpara 29Jan 2017
Assessments
Serial blood samples for PK analy sis will be collected on Day  1 (and Day  4 and Day  7 for t he 
subjects of Japanese descent) for the determination of parath yroid hormone (PTH) 
concentrations (original and baseline- adjusted) at pre -dose and up to 24 hours post dose. 
These blood samples will be collected according to the Schedule of Assessments.
Serial blood samples for PD analy sis will be collected on Day  1 (and Day  4 and Day  7 for the 
subjects of Japanese descent) at pre -dose and up to 24 hours post dose for the determination 
of serum calcium, phosphate, and albumin concentrations.
Safety  and tole rability  will be determined through assessment of treatment -emergent adverse 
events (TEAEs) and vital signs, electrocardiogram (ECG) findings, and clinical laboratory  
evaluations on Day  1 pre -dose and up to 24 hours post dose for the non -Hispanic, Caucasia n 
subjects and Day  1 pre -dose and up to 24 hours post last dose (Day  8) for the subjects of 
Japanese descent.
Additional blood samples for safety  purposes will be collected for assessment of anti- PTH 
antibodies.
Follow -up
A post treatment follow -up visit will be completed 30 (±2) day s after the last dose of 
investigational product for each subject.
Shire CONFIDENTIAL Page 35
SHP634 -102 Protocol
Natpara 29Jan 2017
3.2 Rationale for Dose Selection and Study Design Elements
The primary  objective of this study  is to compare the PK profile of plasma rhPTH(1 -84) between 
subjects of Japanese descent and non- Hispanic, Caucasian volunteers. Although endogenous 
PTH levels are different between healthy subjects and patients with hy poparathy roidism, 
historically , evaluatio ns of different formulations, injection devices and dose proportionality , 
with PK as the primary  objective, have been conducted in healthy  subjects due to the distinct PK 
profile of plasma rhPTH(1 -84) following subcutaneous administration compared to endog enous 
PTH. The PK profile of rhPTH(1 -84) following subcutaneous administration had been shown to 
be similar between healthy  subjects and patients with hy poparathy roidism in previous studies. 
Therefore, this study  is to be conducted in healthy  subjects. Due to the presence of endogenous 
PTH in healthy subjects and that the current PTH assay  measures the total PTH concentration 
(combination of both endogenous PTH and rhPTH [the assay  cannot distinguish between 
endogenous PTH and administered rhPTH(1 -84)]), th e PK anal ysis will be performed based on 
both the original and baseline -adjusted PTH concentrations. Due to the potential differences in 
body  weight between enrolled subjects of Japanese descent and non- Hispanic, Caucasian 
subjects , in addition to the non -body  weight adjusted PK parameters we will also use body  
weight -adjusted PK parameters for comparison.
rhPTH(1 -84) (Natpara),  is currentl y approved in the US at doses of 25, 50, 75 and 100µg 
administered once daily . rhPTH(1- 84) has demonstrated dose -propo rtional PKs over this dose 
range in studies performed in the western countries. No significant differences in either the PKs 
or PDs of  rhPTH(1- 84) are anticipated between Japanese and non -Japanese; therefore, the 
100µg dose, the highest marketed dose, wil l be used in this study  for direct comparative 
purposes. Further doses of 25µg and 50µg will be used in the subjects of Japanese descent to 
examine the dose proportionality  of PKs in Japanese subjects 
Group comparison of the PK, PD, and safet y of rhPTH(1 -84) will be evaluated after a single 
dose administration in this study . Following subcutaneous administration of  rhPTH(1- 84) at 
100µg, plasma PTH levels quickly  increase and reach the first peak concentration 
(approximately  150pg/mL) at around 0.5 hour post dose, which is then followed by  a second 
peak of a similar magnitude at 2 -3 hours post dose. After the second peak, PTH levels decline 
quickly , with an estimated terminal half- life of about 1-2 hours. PTH levels return to baseline at 
about 12 hours post dose. Therefore there is no accumulation of plasma rhPTH after repeat 
dosing, and single dose treatment is considered sufficient to characterize the comparative PKs of 
rhPTH in this study  at that dose. 
To examine the PK dose -proportionality  of rhPTH(1-84) in the subjects of Japanese descent, 
Japanese subjects will receive single, SC doses of 25µg, 50µg, and 100µg rhPTH(1- 84) and PK 
parameters will be evaluated for dose proportionality .  
3.3 Duration and Study Completion Definition
The subject’s maximum durat ion of participation is expected to be approximately  62 day s for the 
non-Hispanic, Caucasian volunteers and 68 day s for the subjects of Japanese descent. The study  
will be completed in approximately  9 weeks
.
Shire CONFIDENTIAL Page 36
SHP634 -102 Protocol
Natpara 29Jan 2017
The Study  Completion Date is defined as the date the final subject, across all sites, completes 
their final protocol -defined assessment. Please note that this includes the follow -up visit or 
contact, whichever is later. The Study  Completion Date is used to ascertain timing for study  
results posting and reporting.
3.4 Sites and Regions
It is anticipated that this study  will be performed at 1 study  site within the United States.
Shire CONFIDENTIAL Page 37
SHP634 -102 Protocol
Natpara 29Jan 2017
4. STUDY POPULATION
Each subject must participate in the informed consent process and provide written informed 
consent before an y proced ures specified in the protocol are performed.
4.1 Inclusion Criteria
Subjects cannot be enrolled before all inclusion criteria (including test results) are confirmed.
1. Ability  to voluntaril y provide written, signed, and dated informed consent as applicable to 
participate in the stud y.
2. An understanding, ability, and willingness to full y comply  with study  procedures and 
restrictions.
3. Age 18 -
65 inclusive at the time of consent.  The date of signature of the informed consent 
is defined as the beginning of the screen ing period.  This inclusion criterion will only  be 
assessed at the first screening visit.
4. Subjects must be either:
a.A subject of Japanese descent born in Japan, who has resided outside of Japan for no 
longer than 5 years and is of Japanese parentage, define d as having 2 Japanese parents, 
and 4 Japanese grandparents, all born in Japan.
b.A non-Hispanic, Caucasian subject who has 2 non- Hispanic, Caucasian parents and 4 
non-Hispanic, Caucasian grandparents.
5. Male or nonpregnant, nonlactating female who agrees to c ompl y with an y applicable 
contraceptive requirements of the protocol or females of nonchildbearing potential.
6. Considered “healthy ” by the investigator.  Healthy status is defined by  absence of evidence 
of an y active or chronic disease following a detailed medical and surgical history , a 
complete ph ysical examination including vital signs, 12 -lead ECG, hematology , blood 
chemistry , and urinal ysis.
7. Body mass index between 18.5 and 25 kg/m², inclusive, with a body  weight ≥45kg 
(99lbs). This inclusion criterion will only  be assessed at the first screening visit.
8. Willing and able to consume standardized meals during the confinement period of the 
study . All participants will be required to consume the identical meals on study  days when 
serial PK and PD blood sampl es are collected.
9. A clinical safety  laboratory  parameter of hemoglobin greater than 11.7g/dl (females) or 
13.1g/dl (males) and less than 16g/dl (females) or 17.4g/dl (males) .
10. Total serum calcium within laboratory  normal limits.
11. Serum parath yroid hormone (P TH) levels within laboratory  normal limits.
Shire CONFIDENTIAL Page 38
SHP634 -102 Protocol
Natpara 29Jan 2017
4.2 Exclusion Criteria
Subjects are excluded from the study  if an y of the following exclusion criteria are met:
1. History  of any  hematological, hepatic, respiratory, cardiovascular, renal, neurological or 
psychiatric d isease, gall bladder removal, or current or recurrent disease that could affect 
the action, absorption, or disposition of the investigational product, or clinical or laboratory  
assessments.
2. Current or relevant history  of phy sical or ps ychiatric illness, any medical disorder that may 
require treatment or make the subject unlikel y to fully  complete the stud y, or an y condition 
that presents undue risk from the investigational product or procedures.
3. Known or suspected intolerance or h ypersensitivity to the inve stigational product(s), 
closely -related compounds, or any  of the stated ingredients.
4. Significant illness, as judged b y the investigator, within 2 weeks of the first dose of 
investigational product.
5. Known history  of alcohol or other substance abuse within t he last y ear.
6. Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to 
receiving the first dose of investigational product.
7. Use of the following prior to administration of investigational product within:
30 day s –loop diuretic s, lithium, antacids, sy stemic corticosteroids (medical judgment is 
required b y the investigator. Primarily high doses of systemic corticosteroids [eg, 
prednisone] should be excluded. Stable doses of hy drocortisone [eg, as treatment for 
Addison’s disease] may  be acceptable).
3 months – calcitonin, cinacalcet h ydrochloride, treatment with rhPTH(1 -84) or 
N-terminal PTH or PTH- related peptide fragments or analogs
For females: changes in hormone replacement therap y within 3 months are excluded. 
Stable ( ≥3 month s) hormone replacement therap y is acceptable.
6 months – fluoride tablets, oral bisphosphonates, methotrexate, growth hormone, 
digoxin, raloxifene or similar selective estrogen receptor modulators (SERMs)
12 months – intravenous bisphosphonates, drug or al cohol abuse, as determined by  the 
investigator
8. Confirmed sy stolic blood pressure (BP) >139mmHg or <89mmHg, and diastolic BP 
>89mmHg or <49mmHg.
9. Twelve -lead ECG demonstrating measure of time between the start of the Q wave and the 
end of the T wave using Fr idericia’s formula in an electrocardiogram (QTcF) >450msec at 
screening.  If QTcF exceeds 450msec, the ECG should be repeated 2 more times and the 
average of the 3 QTcF values should be used to determine the subject’s eligibility .
10. Positive screen for drugs of abuse at screening or drugs of abuse or alcohol on Day  -1.
Shire CONFIDENTIAL Page 39
SHP634 -102 Protocol
Natpara 29Jan 2017
11. Male subjects who consume more than 21 units of alcohol per week or 3 units per day .  
Female subjects who consume more than 14 units of alcohol per week or 2 units per day .  
(1 alcohol unit=1 b eer or 1 wine (5oz/150 mL) or 1 liquor (1.5oz/40 mL) or 0.75 oz 
alcohol).
12. Positive human immunodeficiency  virus (HIV), hepatitis B surface antigen (HBsAg), or 
HCV antibody  screen.
13. Use of tobacco in an y form (eg, smoking or chewing) or other nicotine -contai ning products 
in any  form (eg, gum, patch).  Ex- users must report that they  have stopped using tobacco 
for at least 30 day s prior to receiving the first dose of investigational product.
14. Routine consumption of more than 2 units of caffeine per day  or subjec ts who experience 
caffeine withdrawal headaches.  (1 caffeine unit is contained in the following items:  one 
6oz (180 mL) cup of coffee, two 12 oz (360 mL) cans of cola, one 12 oz cup of tea, three 
1oz (85 g) chocolate bars.  Decaffeinated coffee, tea, o r cola are not considered to contain 
caffeine).
15. Prior screen failure, randomization, participation, or enrollment in this study or prior 
exposure to any  exogenous PTH, PTH fragments or analogs.
16. Current use of an y medication (including over -the-counter, her bal, or homeopathic 
preparations; with the exception of hormonal replacement therap y or hormonal 
contraceptives and occasional use of ibuprofen and acetaminophen). Current use is defined 
as use within 14 day s of the first dose of investigational product.
17. H istory  of abnormalities of calcium homeostasis including hy perparathy roidism, 
hypoparathy roidism, hy perthy roidism, osteoporosis, Cushing’s sy ndrome, hy percalcemia, 
hypocalcemia, or any  other calcium disorder.
4.3 Restrictions 
1.Subjects should refrain from stre nuous phy sical exercise 48 hours prior to admission to the 
CRC and during the in -house stay s at the CRC.
2.Subjects should refrain from consuming grapefruit, Seville oranges, and products containing 
these items from 7 day s prior to Day  1 of the first treatment period through the completion of 
the last treatment period.
3.Subjects should refrain from alcohol 48 hours prior to admission to the CRC and during the 
in-house stay  at the CRC.
4.Subjects should refrain from use of tobacco or an y products containing nicot ine within 
30days of Day  1 of the first treatment period through the completion of the last treatment 
period.
5.Subjects should refrain from taking or regularl y using an y medication (including 
over-the-counter multivitamin, herbal, or homeopathic preparatio ns) with the exception of 
those listed in Section 5.2 from 14 day s prior to receiving the first dose of the investigational 
Shire CONFIDENTIAL Page 40
SHP634 -102 Protocol
Natpara 29Jan 2017
product through the completion of the discharge assessments and procedures at Treatment 
Period 2.
6. Subjects should refrain from foods or beverages containing caffeine/xanthine 48 hours prior 
to admission to the CRC and during the in -house stay  at the CRC.
7.On Day  -1, Day  1, Day  4, and Day  7 when the investigational product is to be administered, 
subjects will be required to fast for appr oximately  8 hours prior to dose of administration and 
continuing through 2 hours after administration of the investigational product. Water will be 
allowed ad libitum. 
8.
Subjects will be required to follow standardized meal schedules and eat the meals provi ded 
by the site while housed in the CRC. No outside food or beverages (including gum, mints, 
etc.) will be permitted. Menus will be identical for all subjects at the CRC. Copies of the 
menus will be provided to the sponsor for approval prior to the start o f the study . While 
confined, the total dail y nutritional composition should be approximately  50% carboh ydrate, 
35% fat, and 15% protein. The daily  caloric intake per subject should not exceed 
approximately  3200 kcal.
4.4 Reproductive Potential
4.4.1 Female Contracep tion
Sexually  active females of childbearing potential should be using an acceptable form of 
contraception. Females of childbearing potential must be advised to use acceptable 
contraceptives throughout the study
 period and for 30 day s following the last dose of 
investigational product. If hormonal contraceptives are used, they  should be administered 
according to the package insert. Females of childbearing potential who are not currentl y sexually 
active must agree to use acceptable contraception, as defined below, if they become sexually  
active during the period of the study  and for 30 day s following the last dose of investigational 
product.
Female subjects should be either:
Postmenopausal (12 consecutive months of spontaneous amenorrhea with follicle -stimula ting 
hormone [FSH] concentrations in the laboratory  post menopausal range). 
Surgically  sterile (having undergone one of the following surgical procedures: hy sterectom y, 
bilateral tubal ligation, bilateral oophorectom y or bilateral salpingectom y) and at le ast 
6weeks post sterilization, or
Females of childbearing potential with a negative serum -hCG pregnancy  test at the 
screening visit and at Day  -1. Females of childbearing potential must agree to abstain from 
sexual activity  that could result in pregnanc y or agree to use acceptable methods of 
contraception.
Acceptable methods of contraception are:
Intrauterine devices plus condoms
Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Shire CONFIDENTIAL Page 41
SHP634 -102 Protocol
Natpara 29Jan 2017
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the first dose of investigational product, plus condoms. Note: If subject 
becomes sexually  active during the study , they  should use 1 of the other acceptable methods 
noted above in add ition to the hormonal contraceptive until it has been stabilized for 30 days.
4.4.2 Male Contraception
Male subjects must be advised to use acceptable contraceptives throughout the study  period and 
for 3 months following the dose of investigational product. Mal e subjects must be advised not to 
donate sperm during the course of the study  and within 3 months of last dose of investigational 
product. Acceptable methods of contraception for male subjects are:
Double-barrier methods (eg, condoms with spermicidal gel o r foam)
4.5 Discontinuation of Subjects
A subject may  withdraw from the study  at any  time for an y reason without prejudice to their 
future medical care b y the physician or at the institution. The investigator or sponsor may  
withdraw the subject at any  time (e g, in the interest of subject safet y). The investigator is 
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
If investigational product is discontinued, regardless of the reason, the early wi thdrawal 
evaluations listed in Table 1 are to be performed as completely  as possible. Whenever possible, 
all discontinued subjects should also undergo the protocol- specified follow -up. Comments 
(spontaneous or elicited) or complaints made b y the subject mu st be recorded in the source 
documents. The reason for termination and date of stopping investigational product must be 
recorded in the source documents.
Enrolled subjects who discontinue from the study  may  be replaced at the sponsor’s discretion.
4.5.1 Reasons for Discontinuation
The reason for withdrawal must be determined b y the investigator and recorded in the subject’s 
medical record. If a subject is withdrawn for more than 1 reason, each reason should be 
documented in the source document and the most clinic ally relevant reason should be noted.
Reasons for discontinuation include but are not limited to:
Adverse event
Protocol deviation
Withdrawal by  subject
Physician decision
Other {If “Other” is selected, the investigator must specify  the reason }
Shire CONFIDENTIAL Page 42
SHP634 -102 Protocol
Natpara 29Jan 2017
4.5.2 Subjects “Lost to Follow -up” Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an y subject lost to follow -up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations and return any unused investigation al product.
Shire CONFIDENTIAL Page 43
SHP634 -102 Protocol
Natpara 29Jan 2017
5. PRIOR AND CONCOMITAN T TREATMENT
5.1 Prior Treatment
Prior treatment includes all treatment (including but not limited to herbal treatments, vitamins, 
nonpharmacological treatments such as psychotherap y as appropriate) received within 30 days 
(or PKequivalent of 5 half-lives, whichever is longer )of the date of dose of investigational 
product. Prior treatment information must be recorded on t he source documentation.
5.2 Concomitant Treatment 
Concomitant treatment refers to all treatment taken between t he dates of the first dose of 
investigational product and the end of the follow -up period, inclusive. Concomitant treatment 
information must be recorded on the appropria te source document .
5.2.1 Permitted Treatment
Subjects should refrain from taking an y medicat ions (excluding those medications listed below) 
during the course of the study . Any medication which is considered necessary for the subject’s 
safet y and well -being may  be given at the discretion of the investigator. The administration of all 
medications ( including investigational products) must be listed on the appropriate source 
document.
Medications permitted during the stud y are listed below:
Hormonal contraceptives for females of childbearing potential administered according to the 
package insert (see Section 4.4.1)
Hormone replacement therap y that has been in use for at least 30 day s prior to date of first 
dose of rhPTH(1
-84)
Occasional use of a nonsteroidal anti -inflammatory  drug as prescribed by  the principal 
investigator (or delegate)
Shire CONFIDENTIAL Page 44
SHP634 -102 Protocol
Natpara 29Jan 2017
6. INVESTIGATION AL PRODUCT
6.1 Identity of Investigational Product
The test product is rhPTH(1-84), which will be provided as a multiple dose, dual chamber, glass 
cartridge containing a sterile lyophilized powder and a sterile diluent for reconstitution at doses 
of 25µg, 50µg and 100µg.
The study  drug cartridge (together with the study  drug cartridge holder) is initially  placed onto a 
mixing device to break the internal seal and allow the ly ophilized powder and diluent to fully  
mix. Once mixed, the study  drug and cartridge are placed into the Haselmeier injector pen in 
preparation for dosing.
Please note that in each administration of the drug by  the pen injector (Haselmeier), a sterile, 
disposable pen needle is used and is specified as a Becton -Dickinson (BDTM) 0.25 mm x 8 mm 
(31G x 5/16”).
Additional information related to the investigational product, including preparation and 
administration, is provided in the current rhPTH(1 -84) investigator brochure, and in an 
investigational product preparation and administration manual th at will be provided.
6.1.1 Blinding the Treatment Assignment
Not Applicable.
6.2 Administration of Investigational Product(s)
6.2.1 Allocation of Subjects to Treatment
This is an open -label study .
Subject numbers are assigned to all subjects as they consent to take part i n the study . Within each 
site (numbered uniquel y within a protocol), the subject number is assigned to subjects according 
to the sequence of presentation for study  participation. This will be a 4-digit number starting at 
0001.
For eligible subjects, the su bject number will be the identify ing number used throughout the 
CRF.
Once a subject number has been assigned, that number must not be used again if, for example, a 
subject is withdrawn from the study . If a subject number is allocated incorrectl y, the clini cal 
research associate/stud y monitor must be notified as soon as the error is discovered.
Investigational product packaging identification numbers, separate from subject numbers, may  
also be assigned to subjects for specific treatment assignment as dictate d by the study . In these 
cases, the same investigational product packing identification number may  not be assigned to 
more than 1 subject.
Shire CONFIDENTIAL Page 45
SHP634 -102 Protocol
Natpara 29Jan 2017
Each eligible subject will be assigned to 1 study drug cartridge (with a unique identifier). Each 
study  drug cartridg e should only  be used for the subject to which it is assigned. Although each 
study  drug cartridge holds multiple doses, only  1 dose from the cartridge must be used for the 
subject it is assigned to. Study  drug cartridges and injector pens must be regarded as single use 
only and never used on more than 1 subject.
A study  drug allocation scheme will be provided. The study drug allocation scheme must be 
maintained securel y in the pharmacy.
6.2.2 Dosing
After each subject has completed the screening process and found to be eligible to proceed to 
dosing (inclusive of all clinical laboratory  values), the subject will be assigned a study  cartridge, 
mixing device and injector pen and, following preparation of the stud y drug, will be administered 
a single dose of investiga tional product in the mid -thigh on the morning of Day 1 (for all study  
subjects) and D ays 4 and 7 (for subjects of Japanese descent onl y). A detailed pharmacy  manual 
will be provided that describes the materials to be used, the preparation of materials and
administration of study  drug.
6.2.3 Unblinding the Treatment Assignment
Not Applicable.
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Labeling
The study  site will receive open label supplies of investigational product, injection pens and 
mixing devices required fo r dosing.
All clinical supplies will be manufactured, tested, labeled and released according to current legal 
and local country  specific regulatory requirements and will comply  with Good Manufacturing 
Practices.
Space is allocated on the label so that the site representative can record a unique subject 
identifier and initials.
Additional labels may , on a case- by-case basis, be applied to the investigational product in order 
to satisfy  local or institutional requirements, but must not:
Contradict the clinica l study  label
Obscure the clinical study label
Identify  the study  subject by  name
Additional labels may  not be added without the sponsor’s prior full agreement.
In addition to labeling requirements for the investigative stud y drug, rhPTH(1 -84), mixing 
devices and injector pens must also be labeled with the unique subject identifier. One mixing 
Shire CONFIDENTIAL Page 46
SHP634 -102 Protocol
Natpara 29Jan 2017
device and 1 injector pen will be supplied for each subject taking part in the study for each dose . 
Mixing devices and injector pens must never be used between stud ysubjects.
6.3.2 Packaging
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.3 Storage
The investigator has overall responsibility  for ensuring that investigational product is stored in a 
secure, limited -access location. L imited responsibility  may  be delegated to the pharmacy  or 
member of the stud y team, but this delegation must be documented. Investigational products are 
distributed by  the pharmacy  or nominated member of the site study  team. The 
pharmacist/nominated study  team member will enter the unique subject identifier on the injector 
pen (containing the stud
y drug cartridge) as they are distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperat ure monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of t he study  and that 
records are maintained; the temperature should be monitored continuously  by using either an 
in-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any  excursi on from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
6.4 Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry  out 
this protocol for the agreed- upon number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment content and 
condition. Accurate records of all investigational product dispensed, used, returned, and/or 
destro yed must be maintained as detailed further in this section.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequa tely trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
Shire CONFIDENTIAL Page 47
SHP634 -102 Protocol
Natpara 29Jan 2017
The investigator or his/her designee (as documented by  the investigator in the applicable stud y 
delegation of authorit y form) will administer the investigational product only to subjects 
included in this study  following the procedures set out in the study  protocol. Each subject will be 
given onl y the investigational product carr ying his/her treatment assignment. All administered 
investigational product will be documented on the source documents and/or other investigational 
product record.
No investigational product stock or returned inventory  from a Shire -sponsored study  may  be 
removed from the site where originall y shipped without prior knowledge and consent b y the 
sponsor. If such transfer is authorized by  the sponsor, all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records.
At the end of the stud y, or as instructed b y the sponsor, all unused stock , and empty /used 
investigational product packaging are to be sent to a nomin ated contractor on behalf of the 
sponsor. I nvestigational product s being returned to the sponsor’s designated contractors must be 
counted and verified b y clinical site personnel and the sponsor. For unused supplies where the 
original supplied tamper -evident feature is verified as intact, the tamper- evident feature must not 
be broken and the labeled amount is to be documented in lieu of counting. Shipment return 
forms, when used, must be signed prior to shipment from the site. Returned investigational 
produc ts, if possible, must be packed in a tamper -evident manner to ensure product integrity . 
Contact the sponsor for authorization to return any investigational product prior to shipment. 
Shipment of all returned investigational product must comply  with local, state, and national laws.
Based on entries in the site drug accountability  forms, it must be possible to reconcile 
investigational products delivered with those used and returned. All investigational products 
must be accounted for and all discrepancies inv estigated and documented to the sponsor’s 
satisfaction.
6.5 Subject Compliance
The investigator/nominated person will record details on the drug accountability  log(s) and/or 
source documents of study  drug administration (including which thigh was used) and dosing 
details (time, date, dose level) .
6.6 Retention of Bioavailability and Bioequivalence Testing Samples
Not Applicable.
Shire CONFIDENTIAL Page 48
SHP634 -102 Protocol
Natpara 29Jan 2017
7. STUDY PROCEDURES
7.1 Study Schedule
See Table 1, Table 2and Table 3 for stud y procedures.
The following “priorit y order” will be in effect wh en more than 1 procedure or assessment is 
required at a particular time point.
Spontaneous or solicited adverse event (AE) reporting
Electrocardiogram (ECG)
Vital signs
Pharmacod ynamic blood sampling
Anti- PTH blood sampling
Clinical laboratory  tests
PK blo od sampling
Physical examination
NOTE: Blood sampling for PD 
and PK evaluation must be performed at the precise protocol -
scheduled time. Actual sampling time(s) must be accuratel y recorded in the source document.
7.1.1 Screening Period
Screening procedures must be completed within 28 day s prior to receiving the dose of 
investigational product. All screening assessments and procedures are to be performed b y the 
principal investigator or a qualified designee. See Table 1 for a complete list of screening 
procedures to be performed. I mmediatel y before dosing on Day 1 (but still within the screening 
period), subjects will check into the CRC ( Day -1) for an overnight stay  prior to dosing on Day
1. Eligibility  procedures performed on Day -1 must be confirmed as meeting inclusion/exclusion 
criteria before dosing on Day 1.
Written, signed, and dated informed consent from the subject prior to the performance of an y 
study -related procedures must be obtained by  the principal investigator or a designee. A copy  of 
the signed informed consent form must be given to the subject for their records.
7.1.1.1 Screening Failure
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least 1 of the exclusion criteria and has not been enrolled or administered 
investigational product(s).
7.1.1.2 Rescreening of Subjects
Subjects who fail to meet all inclusion/exclusion criteria will not be permitted to be rescreened 
for the stud y at an y point.
Shire CONFIDENTIAL Page 49
SHP634 -102 Protocol
Natpara 29Jan 2017
Eligible subjects who meet all inclusion/exclusion criteria but are unable to participate in the 
study  due to scheduling conflicts/timing may  be rescreened based on investigator discretion and 
sponsor approval should their availability  to participate fall outside the screening window. In 
these cases, a new screening nu mber must be assigned for each subject who is rescreened and a 
new informed consent form must be signed.
7.1.2 Treatment Period
7.1.2.1 Days 1 to 8
Study  assessments for Day  1 to Day  8 of the treatment period are outlined in Table 1,Table 2 , 
andTable 3. Administration of investigational product will occur on Day  1 (all study  subjects) of 
the treatment period and Day s 4 and 7 (subjects of Japanese descent) of the treatment period.
Subjects will be discharged from the CRC following completion of the last study  assessment on 
Day 2 (all non- Hispanic, Caucasian subjects) and Day  8 (all subjects of Japanese descent) of the 
treatment period.
7.1.2.2 Final Visit
For this study , the final visit will be the follow -up visit, which is intended to be an out- patient 
clinic visit.
7.1.3 Follow -up Pe riod
The follow -up period for this protocol is 30±2 days after the dose of investigational product. At 
the end of this period there will be a follow -up visit to obtain a blood sample for clinical safet y 
labs, to obtain a blood sample for anti- PTH antibodie s, and to query  for SAEs, AEs, and 
concomitant treatments. All AEs and SAEs that are not resolved at the time of this contact will 
be followed to closure (see Section 8.1.)
7.1.4
Additional Care of Subjects after the Study
No aftercare is planned for this study .
7.2 Study Evaluations and Procedures
7.2.1 Demographic and Other Baseline Characteristics
7.2.1.1 Demographics
Demographic information will be collected at the initial screening visit. I nformation to be 
collected will include:
Date of birth
Sex
Race and ethnicity
Shire CONFIDENTIAL Page 50
SHP634 -102 Protocol
Natpara 29Jan 2017
7.2.2 Safety
The name and address of each third part y vendor (eg, clinical laboratory ) used in this study  will 
be maintained in the investigator’s and sponsor’s files.
Actual safety  assessment times will be monitored and recorded. The sponsor’s expectation is that 
the investigator will ensure that every  effort is made to perform all assessments at the precise 
protocol -scheduled time. Any  safet y assessment that deviates from the scheduled assessment 
time set forth in the protocol by  more than ±15 minutes will be considere d a protocol deviation 
(unless otherwise noted in the protocol).
Adverse events (defined as AEs occurring from the time of informed consent signature to the 
dose of investigational product), TEAEs (all AEs occurring after the treatment), prior medication 
and concomitant medication use will be assessed and monitored from the time the subject signs 
the informed consent form to completion of study (including to time of screen failure or drop 
out/discontinuation). While confined in the CRC, subject safet y will also be closel y monitored 
through BP measurements, ECG measurement, clinical safet y labs and ph ysician oversight.
In the event anti-PTH antibodies are detected following anal ysis for a subject, the investigator 
will be notified by  the sponsor. I t will be the investigator’s responsibility  to notify  the subject.
7.2.2.1 Medical and Medication History
A complete medical and medication history , as well as demographic information, will be 
performed at the screening visit/time points described in Table 1 by a qualified l icensed 
physician, ph ysician’s assistant, or a nurse practitioner. The medical history  will be reviewed and 
recorded, including:
Recent ingestion of medication (30 days prior to entering the screening period)
History  of respiratory , cardiovascular, renal, gastrointestinal, hepatic, endocrine, 
hematological, neurological, psy chiatric, and other diseases
7.2.2.2 Physical Examination (Including Height and Weight)
A complete ph ysical examination will be performed at the time points described in Table 1, 
Table 2, andTable 3by a qualified licensed ph ysician, phy sician’s assistant, or nurse 
practitioner.
The phy sical examination will include a review of the following bod y systems:
General appearance
Skin
Head, ey es, ears, nose, and throat
Spine/neck/thy roid
Musculoskele tal
Respiratory
Shire CONFIDENTIAL Page 51
SHP634 -102 Protocol
Natpara 29Jan 2017
Cardiovascular
Neurological
Abdomen (including liver and kidney s)
Clinically  significant abnormalities identified at the screening visit will be documented in the 
subject’s source documents. Changes after the screening visit will be captur ed as AEs on the AE 
source documentation , as deemed b y the investigator.
7.2.2.3 Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had an y health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (Please refer to Section 8, 
Adverse and Serious Adverse Events Assessment.)
7.2.2.4 Vital Signs
BLOOD PRESSURE AND PULSE RATE
Blood pressure and pulse rate will be measured at times specified in Table 1, Table 2 and Table 3
of this protocol. Additional BP and pulse rate measurements may  be performed, as determined 
by the investigator, in order to ensure appropriate monitoring of subject safety  and accurate 
recordi ng of vital sign measurements. Any  changes from baseline which are deemed clinicall y 
significant b y the investigator areto be recorded as an AE.
The same method for obtaining BP measurement (auscultatory  or oscillometric) should be used 
throughout the stu
dy for all subjects (and documented). In addition, the conditions of vital sign 
measurements should be controlled and as consistent as possible during the study , in order to 
minimize external variability  of the readings. It is advised that measurements be collected at a 
comfortable room temperature with little to no background noise, using the same (appropriatel y 
sized) cuff placed at the same location of the same arm during the study . The bladder deflation 
rate should be deflated (calibrated for oscillometric method or manuall y by auscultatory  method) 
at a rate of 2 -
3 mmHg/s (and the first and last audible sounds recorded as s ystolic and diastolic 
pressure) after at least 5 minutes of rest in the assumed position.
The cuff should have a bladder length that is 80% and a width that is at least 40% of arm 
circumference (a length -to-width ratio of 2:1). 
The subject should be asked to remove all clothing that covers the location of cuff placement. 
The subject should not have exercised or consumed caffeine, alcoh ol, or nicotine within 30 
minutes of collection. The subject should be instructed to relax as much as possible for at least 5 
minutes prior to collection. The subject should remain quiet during this time and through the 
measurement.
Shire CONFIDENTIAL Page 53
SHP634 -102 Protocol
Natpara 29Jan 2017
BODY TEMPERATURE
Oral temperature should be taken by placing a digital thermometer under the tongue as per study 
site documented p rocedures and the temperature reported in degrees Celsius.
7.2.2.5 Clinical Laboratory Evaluations
All clinical laboratory  assay s will be performed according to the laboratory ’s normal procedures. 
Reference ranges are to be supplied by  the laboratory  and will be u sed to assess the clinical 
laboratory  data for clinical significance and out-of-range pathological changes. The investigator 
should assess out -
of-range clinical laboratory  values for clinical significance, indicating if the 
value(s) is/are not clinically  significant or clinically  significant. Abnormal clinical laboratory  
values, which are unexpected or not explained by  the subject’s clinical condition, may , at the 
discretion of the investigator or sponsor, be repeated as soon as possible until confirmed, 
explained, or resolved.
The following clinical laboratory  assessments will be performed:
BIOCHEMISTRY
Blood samples (8.5 mL) for serum biochemistry  will be collected into a red top gel separator 
tube at the time points described in Table 1, Table 2and Table 3. The followi ng parameters will 
be assessed:
Sodium Phosphorus -hCGb
Potassium Total protein Magnesium
Glucose Total CO 2(Bicarbonate) PTHc
Blood urea nitrogen Albumin FSHb
Creatinine Aspartate transaminase 
Calcium Alanine transaminase 
Chlori de Gamma glutamy l transferase 
Thyroid stimulating hormone (TSH)aAlkaline phosphatase 
Thyroxine (T 4total)aTotal bilirubin 
Triiodothy ronine (T 3)aUric acid
CO 2=carbon dioxide; FSH= follicle stimulating hormone; T 3=triiodothyronine; T 4=thyroxine ; TSH=thyroid stimulating 
hormone
aSee Table 1,Table 2and Table 3 .
bFemales only.
cParathyroid hormone at screening and Day -1 is for baseline eligibility use only and not for PK analysis.
Shire CONFIDENTIAL Page 54
SHP634 -102 Protocol
Natpara 29Jan 2017
HEMATOLOGY
Blood samples (4mL) for hematology  will be collect ed into a K 2-EDTA 
(ethy lenediaminetetraacetic acid) tube at the time points described in Table 1,Table 2and Table 
3. The following parameters will be assessed:
Hemoglobin Total neutrophils (absolute)
Hematocrit Eosinophils (absolute)
Red blood cells Monocy tes (absolute)
Platelet count Basophils (absolute)
White blood cell count; total and differential Lym phocy tes (absolute)
URINALYSIS
A urine sample for urinaly sis will be collected at the time points described in Table 
1,Table 2
and Table 3
. The fol lowing parameters will be assessed:
pH Blood Nitrites
Glucose Ketones Leukocy te esterase
Protein Bilirubin Specific gravit y
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urinaly sis. At a minimum the microscopic examination will consist of red blood cells, white 
blood cells, casts, and bacteria. 
7.2.2.6 Pregnancy Test
A serum -hCG pregnancy test is required for all females at screening, on admission to the CRC 
on Day  -1 and upon discharge from the CRC on Day 2 (for non-Hispanic, Caucasian subjects) or 
Day 8 (for subjects of Japanese descent) and at the final follow-up visit for all females. In 
addition, a pregnancy  test is required if pregnancy is suspected or on earl y 
withdrawal/termination from the study .
7.2.2.7 Drug and Alc ohol Screen
A urine screen for drugs of abuse and an alcohol breath test will be performed at the time points 
described in Table 1.Additional drug and alcohol screens may  be performed at the investigator’s 
discretion.
Urine samples are to be tested for am phetamines, barbiturates, benzodiazepines, cannabinoids, 
cocaine, methadone, opiate metabolite, and phencyclidine.
Results of urine drug and alcohol screens will be reviewed and verified b y the study monitor, but 
will not be collected in the CRF database.
Shire CONFIDENTIAL Page 55
SHP634 -102 Protocol
Natpara 29Jan 2017
Any positive result for drugs of abuse at screening or drugs of abuse and alcohol on Day  -1 will 
exclude the subject from further participation in the study .
7.2.2.8 Serology Screen
At the screening visit, a blood sample of approximately  8.5mL will be drawn into a serum 
separator tube to test for the presence of HIV, HBsAg, and HCV antibod y.
The test results must be confirmed negative prior to enrollment in the study. If a test result is 
positive, the subject will be excluded from entering the stud y. Results of the virology  screen will 
be reviewed and verified by  the study  monitor, but will not be collected in the CRF database.
Positive serology  results may  be reported to the relevant health authorities by study  site 
personnel 
if required b y law.
7.2.2.9 Electrocardiogram
Twelve -lead ECGs will be performed at the times specified in Table 1, Table 2and Table 3. All 
ECGs will be performed using the equipment supplied by  the CRC.
The following parameters will be recorded in the source documentation : heart rate, time elapsed 
from P wave to R wave in an electrocardiogram (PR), the time between heart beats in an 
electrocardiogram (RR), measure of time for the 3 main deflections in an electrocardiogram 
(QRS), and QT intervals along with information on T and U wave morphology  (T wav es should 
be captured as normal/abnormal; U waves should be captured as absent/normal or abnormal). 
The measure of time between the start of the Q wave and the end of the T wave using Bazett’s 
formula in an electrocardiogram (QTcB) and QTcF will be derived from the data in the database. 
The investigator’s assessment of the ECG tracing as normal or abnormal must be documented, 
and if abnormal, his/her determination of whether the abnormalit y is clinically significant or not 
will be documented on the tracing and the source documentation (if different).
The subject should be asked to remove all clothing that covers the location of lead placement. 
The subject should not have exercised or consumed caffeine within 30 minutes prior to 
collection. The subject must be resting in the supine position for at least 5 minutes prior to 
collecting the ECG.
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads are pla ced in the 
same positions each time in order to achieve precise ECG recordings. 
Triplicate ECG recordings, including a 10 -second rhy thm strip, should be taken at each time 
point. They should be immediately  assessed as valid recordings and if not valid, th ey should be 
repeated. Invalid recordings will not be entered in cluded in the CRF database .
A triplicate ECG recording is to be performed at each time point approximately  2-4 minutes 
apart. The averages of the ECG triplicate collected predose on Day  1 (all subjects) and predose 
on Day s 4 and 7 (subjects of Japanese descent) will serve as the subject’s baseline ECG.
Shire CONFIDENTIAL Page 56
SHP634 -102 Protocol
Natpara 29Jan 2017
To ensure safet y of the subjects, a qualified individual at the investigator site will make 
comparisons to baseline measurements.
If the triplic ate average QTcF interval (calculated online on site) is increased by  >45 msec from 
the baseline or an absolute QTcF value is >500 msec for an y scheduled ECG, then 2 additional 
ECGs will be collected, approximately  2-4 minutes apart, to confirm the origina l measurement. 
If either of the QTcF values from these repeated ECGs remains above the threshold value (>45 
msec from the baseline; or is >500 msec), then a single ECG must be repeated at least hourl y 
until QTcF values from 2 successive ECGs fall below the threshold value that triggered the 
repeat measurement. When triplicate ECGs are collected, the mean of the triplicate 
measurements should be used to trigger the decision to collect follow -up ECGs.
If QTcF values remain above 500 msec (or >45 msec from the baseline) for >4 hours (or sooner 
at the discretion of the investigator) or QTcF intervals get progressivel y longer, the subject 
should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF 
intervals do not return to <500 msec (or to <45 msec above the baseline) after 8 hours of 
monitoring (or sooner at the discretion of the investigator).
If a machine -read QTcF value is prolonged, as defined above, repeat measurements may  not be 
necessary  if a qualified phy sician’s interpretation d etermines that the QTcF values are in the 
acceptable range.
7.2.3 Pharmacokinetic Procedures
The name and address of the bioanal ytical laboratory  (Celerion) for this study  will be maintained 
in the investigator’s files at the site and in the Trial Master File at the sponsor.
Actual PK blood sample collection times versus time of dosing will be monitored. The sponsor’s 
expectation is that the investigator will ensure that every  effort is made to collect all PK blood 
samples at the precise protocol scheduled time. PK blood collection must not deviate from the 
nominal collection time set forth in the protocol by  more than 5 minutes from samples drawn 
within 4 hours postdose or by  more than 15 minutes for samples drawn at 4 hours post dose and 
beyond. Samples drawn outside these parameters will be considered a protocol deviation.
7.2.3.1 Pharmacokinetic Sample Collection and Handling Procedures
Pharmacokinetic blood samples will be collected at the time specified in Table 1,Table 2and 
Table 3 to measure plasma concentratio ns of PTH. A full description of the PK blood collection, 
handling, storage and shipping can be found in the provided laboratory  manual. Plasma sample 
tubes for bioanal ysis must be freezer -safe and identified with freezer -safe labels provided b y the 
CRC. T he labels will contain the following information:
Study  number: SHP634 -
102
Subject identifier
Nominal day
Nominal time
Shire CONFIDENTIAL Page 57
SHP634 -102 Protocol
Natpara 29Jan 2017
Matrix identifier (plasma)
Split (primary  or back- up)
7.2.3.2 Shipment of Plasma Pharmacokinetic Samples
All PK samples should be double- bagged to contain leaks and packed with a sufficient quantit y 
of dry  ice to ensure that they  remain frozen for at least 72 hours to allow for delays in shipment. 
All applicable shipping regulations must be followed. Shipments should be scheduled so that no 
samples arrive on the weekend and should be shipped Monday -Wednesday only  (do not ship on 
a local, regional or national holiday). Samples should be transported to ensure that they  arrive at 
the bioanal ytical laboratory  between the hours of 9:00 AM and 4:00 PM. The recipient 
(Celerion) and primary  Shire contact must be notified by telephone or e -mail when the samples 
are shipped and they  must be provided with the shipment tracking number.
Full directions for shipment of all PK samples, (along with the correspondin g documentation) 
can be found in the laboratory  manual provided under separate cover.
Pharmacokinetic samples will be stored nominally at - 70º C ( -94ºF) prior to and after anal ysis at 
the bioanal ytical labs until their disposal is authorized by  Shire.
7.2.3.3 Plasma Drug Assay Methodology
Plasma sample anal ysis will be performed according to the relevant Standard Operating 
Procedures at the contract bioanaly tical lab (Celerion).
Plasma concentrations will be measured using the most current validated bioanal ytical method. 
In addition, selected plasma samples may  be used to investigate incurred sample reproducibility  
(full details will be described in the bioanal ytical study  plan).
7.2.4 Pharmacodynamic Assessments
The name and address of the bioanal ytical laboratory  (InVen tiv Health) for this study  will be 
maintained in the investigator’s files at the site and in the Trial Master File at the sponsor.
Actual PD blood sample collection times versus time of dosing will be monitored. The sponsor’s 
expectation is that the invest igator will ensure that every  effort is made to collect all PD blood 
samples at the precise protocol scheduled time. Pharmacod ynamic blood collection must not 
deviate from the nominal collection time set forth in the protocol by  more than 5 minutes from 
samples drawn within 4 hours post dose or b y more than 15 minutes for samples drawn at 4 
hours post dose and bey ond. Samples drawn outside these parameters will be considered a 
protocol deviation.
7.2.4.1 Pharmacodynamic Sample Collection and Handling Procedures
Pharmacod ynamic blood samples will be collected at the time specified in Table 1,Table 2and 
Table 3 to measure serum concentrations of calcium, phosphate and albumin. A full description 
of the PD blood collection, handling, storage and shipping can be found in the provided 
Shire CONFIDENTIAL Page 58
SHP634 -102 Protocol
Natpara 29Jan 2017
laboratory  manual. Serum sample tubes for bioanaly sis must be freezer -safe and identified with 
freezer -safe labels provided by  the CRC. The labels will contain the following information:
Study  number: SHP634 -102
Subject identifier
Nomina l day
Nominal time
Matrix identifier (serum)
Analy te (calcium/phosphate or albumin)
Split (primary  or back- up)
7.2.4.2 Shipment of Serum Pharmacodynamic Samples
All PD samples should be double-bagged to contain leaks and packed with a sufficient quantit y 
of dry  ice to ensure that they  remain frozen for at least 72 hours to allow for delays in shipment. 
All applicable shipping regulations must be followed. Shipments should be scheduled so that no 
samples arrive on the weekend and should be shipped Monday -Wednesday only (do not ship on 
a local, regional or national holiday). Samples should be transported to ensure that they  arrive at 
the bioanal ytical laboratory  between the hours of 9:00 AM and 4:00 PM. The recipient 
(inVentiv) and primary  Shire contact must be notif ied by  telephone or e -mail when the samples 
are shipped and they  must be provided with the shipment tracking number.
Full directions for shipment of all PD samples, (along with the corresponding documentation) 
can be found in the laboratory  manual provided under separate cover.
Pharmacod ynamic samples will be stored nominally at -70º C ( -94ºF) prior to and after anal ysis 
at the bioanal ytical labs until their disposal is authorized by  Shire.
7.2.4.3 Serum Pharmacodynamic Assay Methodology
Serum sample anal ysis will be performed according to relevant Standard Operating Procedures at 
the contract bioanal ytical lab (inVentiv Health).
Serum PD concentrations will be measured using the most current validated bioanaly tical 
methods. I n addition, selected serum samples may  be used to investigate incurred sample 
reproducibility  (full details will be described in the bioanal ytical stud y plan). The presence of 
other metabolites or artifacts may  be monitored or quantified as appropriate.
7.2.5 Immunogenicity Testing for Anti -Parathyroi d Hormone Antibodies
The name and address of the bioanal ytical laboratory  (Covance) conducting anti- PTH 
immunogenicit y testing for this study will be maintained in the investigator’s files at the each 
site and in the Trial Master File at the sponsor.
Actua l anti -PTH blood sample collection times versus time of dosing will be monitored. The 
sponsor’s expectation is that the investigator will ensure that every  effort is made to collect all 
Shire CONFIDENTIAL Page 59
SHP634 -102 Protocol
Natpara 29Jan 2017
anti-PTH blood samples at the precise protocol scheduled time. Anti- PTH blood collection will 
be collected on Day  1 prior to dose (within 30 minutes of dose) and at the follow -up visit.
In the event anti-PTH antibodies are detected following anal ysis for a subject, the investigator 
will be notified by  the sponsor. I t will be the investigator’s responsibility  to notify  the subject.
7.2.5.1 Sample Collection and Handling Procedures for Immunogenicity Testing for 
Anti -Parathyroid Hormone Antibodies
Blood samples will be collected at the time specified in Table 1, to detect anti- PTH anti bodies in 
serum. A full description of the anti -PTH blood collection, handling, storage and shipping can be
found in the provided laboratory  manual. Serum sample tubes for bioanal ysis must be freezer -
safe and identified with freezer -safe labels provided by the CRC. The labels will contain the 
following information:
Study  number: SHP634 -102
Subject identifier
Nominal day
Nominal time
Matrix identifier (serum)
Split (primary  or back- up)
7.2.5.2 Anti -Parathyroid Hormone Antibody Assay Methodology
Serum sample anal ysis will be performed according to relevant Standard Operating Procedures at 
the contract bioanal ytical lab (Covance).
Detection of anti -PTH antibodies from serum blood samples will use the most currentl y 
validated bioanal ytical method. 
Shire CONFIDENTIAL Page 60
SHP634 -102 Protocol
Natpara 29Jan 2017
7.2.6 Volume of Blood to B e Drawn from Each Subject
Table 4 Volume of Blood to Be Drawn from Each Subject
Caucasian Japanese
AssessmentSample 
Volume (mL)Number of 
SamplesTotal 
Volume 
(mL)Number of 
SamplesTotal 
Volume 
(mL)
Pharm acokinetic samplesa4 18 72 54 216
Serum PTH samplea2 2 4 2 4
Pharm acody namic samplesa6 5 30 15 90
HBsAg, HIV, HCVa8.5 1 8.5 1 8.5
Safety Biochemistry, FSH 
and -hCGa, b8.5 4 34 7 59.5
Hem atologya4 4 16 7 28
Anti-PTH Antibody Samplesa3 2 6 2 6
Total mL 170.5 412
-hCG=beta -human chorionic gonadotropin; FSH=follicle stimulating hormone, HBsAg=hepatitis B surface antigen; 
HCV=hepatitis C virus; HIV=human immunodeficiency virus
aIf a catheter is in use for any blood draw or series of blood draws then the first 1 mL is to be discarded. The 1mL discard has 
been taken into account in the table above and the total blood volume required for study.
b-hCG and FSH testing for females only.
During this stud y, it is expected that approximately 412mL of blood will be dra wn from all 
subjects of Japanese descent, regardless of sex. For the non- Hispanic, Caucasian volunteers it is 
expected that 170.5mL  of blood will be drawn, regardless of sex.
Note: The amount of blood to be drawn for each assessment is an estimate. The amo unt of blood 
to be drawn may  vary  according to the instructions provided by  the manufacturer or laboratory  
for an individual assessment; however, the total volume drawn over the course of the stud y 
should be approximately  170.5mL  (non -Hispanic, Caucasian s ubjects) or 412 mL (subjects of 
Japanese descent). When more than 1 blood assessment is to be done at the time point/period, if 
they require the same t ype of tube, the assessments may  be combined.
Shire CONFIDENTIAL Page 61
SHP634 -102 Protocol
Natpara 29Jan 2017
8. ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AEis any  untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily  have a causal relationship with this 
treatme nt. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigati onal) product
(International Conference on Harmonisation [I CH] Guidance E2A 1995).
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.3 .This includes events occurring during the scre ening phase of the 
study , regardless of whether or not investigational product is administered. Where possible, a 
diagnosis rather than a list of sy mptoms should be recorded. If a diagnosis has not been made, 
then each s ymptom should be listed individually . All AEs should be captured on the appropriate 
source documents. In addition to untoward AEs, unexpected benefits outside the investigational 
product indication should also be captured on the AE source documentation .
All AEs must be followed to closure (t he subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investig ator 
does not expect any  further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1 Severity Categorization
The sever ity of AEs must be recorded during the course of the event including the start and stop 
dates for each change in severity. An event that changes in severity should be captured as a new 
event. Worsening of pretreatment events, after initiation of investigat ional product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has bee n administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded in the source documentation ).
The medical assessment of severit y is determined by using the following definitions:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes w ith usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Shire CONFIDENTIAL Page 62
SHP634 -102 Protocol
Natpara 29Jan 2017
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if unde termined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of the 
investigational product is compelling and/or follows a known or suspected response 
pattern to that product, and the event cannot be explained by the subject’s medical 
condition, other therapies, or accident.
Not RelatedThe event can be readily explained by other factors such as the subject’s underlying 
medical condition, concomitant therapy, o r accident and no plausible temporal or 
biologic relationship exists between the investigational product and the event.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the stud y on the source 
documentation . Outcomes are as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved With Sequelae
Recovering/Resolving
Unknown
8.1.4 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory , vital sign, or ECG assessment can represent an AE 
if the change is clinically relevant or if, during treatment with the investigational product, a shift 
of a parameter is observed from a normal value to an abnormal value, or a further worsening of 
an alread y abnormal value. When evaluating such changes, the extent of deviation from the 
reference range, the duration until return to the reference range, either while continuing treatment 
Shire CONFIDENTIAL Page 63
SHP634 -102 Protocol
Natpara 29Jan 2017
or after the end of treatment with the investigational product, and the range of variation of the 
respectiv e parameter within its reference range, must be taken into consideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory , vital sign, or ECG 
values which were not present at the pretreatment value observed closest to the star t of study  
treatment, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (eg, concomitant disease) is found for the 
abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory , vital sign, or ECG parameter is clinicall y 
significant and therefore represents an AE.
8.1.5 Pregnancy
All pregnancies are to be reported from the time informed c onsent is signed until the defined 
follow -up period stated in Section 7.1.3.
Any report of pregnancy  for any  female study  participant or the partner of a male study  
participant must be reported within 24 hours to the Shire Global Pharmacovigilance and Risk
Management Department using the Shire Investigational and Marketed Products Pregnancy  
Report Form. A cop y of the Shire Investigational and Marketed Products Pregnancy Report 
Form (and an y applicable follow -up reports) must also be sent to the contract res earch 
organization (CRO)/Shire medical monitor using the details specified in the emergency  contact 
information section of the protocol. The pregnant female study  participant must be withdrawn 
from the study .
Every  effort should be made to gather informati on regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
30 calendar day s after the initial notification and approximately  30 calendar day s post partum.
Pregnancy  complic ations such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Serious Adverse Event 
and Non -serious AEs Required by  the Protocol Form. Note: An elective abortion is not 
considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Serious Adverse Event and 
Non-serious AEs Required by  the Protocol Form as well as the Shire Investigational and
Marketed Products Pregnancy  Report Form. The test date of the first positive serum/urine -hCG 
test or ultrasound result will determine the pregnancy  onset date.
8.1.6
Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE. 
Shire CONFIDENTIAL Page 64
SHP634 -102 Protocol
Natpara 29Jan 2017
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse – Persistent or sporadic intentional intake of investigational product when used for a 
nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a manner that 
may be detrimental to the individual and/or society
Misuse –Intentional use of investigational product other than as directed or indicated at an y 
dose (Note: this includes a situation where the investigational product is not used as directed 
at the dose prescribed b y the protocol)
Overdose – Intentional or unintentional intake of a dose of investigational product higher 
than the protocol -prescribe d dose
Medication Error –An error made in prescribing, dispensing, administration, and/or use of 
an investigational product. For studies, medication errors are reportable to the sponsor only  
as defined below.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of an expired investigational product should be considered as a 
reportable medication error.
The administration of rhPTH(1- 84) to an eligible volunteer following an excursion in 
temperature requirements (outlined in the pharmacy  manual), without assessment of the 
excursion and permission of the sponsor to proceed, is deemed a medication error.
It is not expected that overdose would occur in this protocol. The investigative product used in 
this study  is supplied in 1 strength onl y, and is administered once onl y per volunteer, b y a trained 
and responsible staff member at the stud y site with sponsor oversight.
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for safe ty information for this study  is the rhPTH(1- 84) investigators brochure 
which the sponsor has provided under separate cover to all investigators.
8.2.2 Reporting Procedures
All initial and follow -up SAE reports must be reported by  the investigator to the Shire G lobal 
Pharmacovigilance and Risk Management Department andthe Shire medical monitor within 24 
hours of the first awareness of the event. Note: The 24-hour reporting requirement for SAEs does 
not apply  to reports of abuse, misuse, overdose, or medication e rrors (see Section 8.1.6) unless 
they result in an SAE.
The investigator must complete, sign, and date the Shire Clinical Study  Serious Adverse Event 
and Non -serious AEs Required by  the Protocol Form and verify  the accuracy  of the information 
recorded on t he form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested) and fax or e -
mail the form to the Shire Global Pharmacovigilance 
and Risk Management Department. A cop y of the Shire Clinical Study  Serious Adverse Event 
and Non -serious AEs Required by the Protocol Form (and any  applicable follow -up reports) 
Shire CONFIDENTIAL Page 65
SHP634 -102 Protocol
Natpara 29Jan 2017
must also be sent to the Shire medical monitor using the details specified in the emergency  
contact information section of the protocol.
8.2.3 Serious Adverse Event D efinition
A serious adverse event (SAE) is any  untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose:
Results in death
Is life -threatening. Note: The term “life -threatening” in the definition of “ serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations that are the result of elective or previously  scheduled surgery  for 
pre-existing conditions and have not worsened after initiation of treatment should not be 
classified as SAEs. For example, an admission for a previ ously scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospitalization for an elective or previousl y scheduled surgery  that meet(s) serious criteria 
must be reported as SAE(s).
Results in persiste nt or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: Important medical events that may  not result in death, 
be life -threatening, or require hospitalization may  be considered an SAE when, based upon 
appropriate medical judgment, they  may  jeopardize the subject and may  require medical or 
surgical intervention to prevent 1 of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency  
room or at home; blood dyscrasias or convulsions that do not result in inpatient 
hospitalization; or the development of drug dependency  or drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow
-up period stated in Section 7.1.3 and must be reported 
to the Shire Global Pharmacovigilance and Risk Management Department andthe Shire medical 
monit or within 24 hours of the first awareness of the event.
In addition, any SAE(s) considered “related” to the investigational product and discovered by  the 
investigator at an y interval after the study has completed must be reported to the Shire Global 
Pharma covigilance and Risk Management Department within 24 hours of the first awareness of 
the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the d ate the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
Shire CONFIDENTIAL Page 66
SHP634 -102 Protocol
Natpara 29Jan 2017
event is considered chronic. I n the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectivel y.
In addition, any  signs or sy mptoms experienced by  the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE,
must be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE tha t results in the subject’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute t o the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of withdrawn should not be selected solel y as a result of the 
subject’s death.
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
Thesponsor is responsible for notify ing the relevant regulatory  authorities and the US centr al 
Institutional Review Boards (IRBs) of related, unexpected SAEs.
In addition the sponsor is responsible for notify ing active sites of all related, unexpected SAEs 
occurring during all interventional studies across the SHP634 clinical program. 
The invest igator is responsible for notify ing the local IRB, local ethics committee (EC), or the 
relevant local regulatory  authority  of all SAEs that occur at his or her site as required.
Shire CONFIDENTIAL Page 67
SHP634 -102 Protocol
Natpara 29Jan 2017
9. DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  the protocol 
from the source documentation to the CRF. A study  monitor will visit each site in accordance 
with the monitoring plan and review the CRF data against the source data for completenes s and 
accuracy . Discrepancies between source data and data entered on the CRF will be addressed by  
qualified site personnel. When a data discrepancy warrants correction, the correction will be 
made b y authorized site personnel. Data collection procedures w ill be discussed with the site at 
the site initiation visit and/or at the investigator’s meeting. Once a subject is randomized, it is 
expected that site personnel will complete the CRF entry  within a reasonable window of the 
subject’s visit.
9.2 Clinical Data 
Management
Data are to be entered into a clinical database as specified in the CRO’s data management plan. 
Quality  control and data validation procedures are applied to ensure the validity  and accuracy  of 
the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Data Handling Considerations
This is an open label study and therefore there are no particular data handling concerns.
9.4 Statistical Analysis Process
The study  will be anal yzed by the sponsor or its agent.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the 
PK, PD, and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information su ch as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. The 
SAP will also include a description of how missing, unused and spurious data will be addressed.
To preserve t he integrit y of the statistical anal ysis and study  conclusions, t he SAP will be 
finalized prior to database lock.
All statistical analy ses will be performed using SAS(SAS I nstitute, Cary , NC 27513). 
9.5 Planned Interim Analysis, Adaptive Design, and Data Mo
nitoring Committee
There is no planned interim analy sis, adaptive design, or data monitoring committee (DMC) in 
this study .
Shire CONFIDENTIAL Page 68
SHP634 -102 Protocol
Natpara 29Jan 2017
9.6 Sample Size Calculation and Power Considerations
No formal calculations were performed to determine sample size for this study . The sample size 
is based on feasibility  and is similar to that of comparable studies.
9.7 Study Population
The following stud y subject populations are defined for this study:
The safety  population includes subjects who have received at least 1 dose of rhPTH(1 -84).
The PK population consists of subjects who receive at least 1 dose of rhPTH(1 -84) and have 
at least 1 evaluable post dose PK concentration value.
The PD population consists of subjects who receive at least 1 dose of rhPTH(1 -84) and have 
at least 1 evaluable post dose PD concentration value.
9.8 Pharmacokinetic and Pharmacodynamic Analyses
9.8.1 Pharmacokinetic Analysis
All the PK analy ses will be performed using the PK set.
A PK evaluation of PTH concentrations and baseline -adjusted PTH concentrations will be 
perfo rmed following the administration of rhPTH(1- 84) administered on Day  1 for non- Hispanic, 
Caucasian subjects and Day s 1, 4 and 7 for subjects of Japanese descent.
Pharmacokinetic parameters will be calculated from original and baseline -adjusted plasma 
conce ntration -time data using noncompartmental methods and all calculations will be based on 
actual sampling times. Baseline is defined as the average Day 1 predose concentration for all 
subjects (and the Day 4 and Day  7 average predose concentration for the su bjects of Japanese 
descent for those respective dosing intervals ). Pharmacokinetic parameters will be estimated 
based on noncompartmental anal ysis and will include, but not be limited to, the following:
Cmax: Maximum concentration occurring at t max
tmax: Time of maximum observed concentration sampled during a dosing interval
AUC last: Area under the curve from the time of dosing to the last measurable concentration

z: First order rate constant associated with the terminal (log linear) portion of the curve
t½:Terminal half -life
CL/F: Apparent clearance
Vdz/F: Apparent volume of distribution
Non-body  weight adjusted and b ody weight -adjusted AUC last, Cmax, CL/F, and Vd z/F will be 
estimated. In addition, dose -normalized baseline adjusted AUClast and Cmax will be calculated.
Shire CONFIDENTIAL Page 69
SHP634 -102 Protocol
Natpara 29Jan 2017
9.8.1.1 Statistical Analysis of Pharmacokinetic Parameters
Individual concentrations (original and baseline-adjusted) and PK parameters (original, baseline-
adjusted, body  weight -adjusted, and dose -normalized -baseline -adjusted) of rhPTH(1 -84) will be
listed and summarized with descriptive statistics (number, arithmetic mean, standard deviation 
[SD], coefficient of variation [CV%], median, minimum, maximum, geometric mean, and %CV 
of geometric mean. The 95% confidence intervals of the geometric means o f PK parameters will 
be presented as well. Figures of individual and mean (±SD) concentration -time profiles of the 
original and baseline -adjusted plasma rhPTH(1- 84) will be generated on linear and semi- log 
scales. The mean plots will be generated b y overla ying the Japanese cohort and Non- Japanese 
cohort. Figures of baseline- adjusted PK parameters and dose -normalized baseline -adjusted PK 
parameters vs dose in Japanese subjects will be generated. Box- Whisker plots for selected PK 
parameter will be generated w ith Japanese cohort and Non- Japanese side by  side. Forest plots of 
geometric mean ratios for selected PK parameters between Japanese cohort vs Non -Japanese 
cohort will be generated.
Dose proportionality  of PKparameters will also be examined for the Japane se subjects. Dose 
proportionality  will be assessed for Cmax and AUC (AUC0 -last) using the power model. The 
power model assumes a linear relationship between the natural log transformed parameter and 
the natural log transformed dose.
ln (Parameter) = α + β × ln (Dose) + Random error
Where α is the intercept, β is the slope, and Random error is a random residual error. Dose 
proportionality  implies that slope = 1 and will be assessed by estimating mean slope with the 
corresponding two si ded 90% confidence interval (CI) from the power model.
In order to compare the PKs of rhPTH(1- 84) between subjects of Japanese descent and matched 
non-Hispanic, Caucasian subjects, the differences of log -transformed PKparameters from the 
rhPTH 100ug dose will be examined between groups using an anal ysis of variance model. The 
geometric mean ratio and its 90% confidence interval (CI) will be provided from the model. 
Baseline -adjusted PK parameters will be the primary  PK endpoints, and other PK parameters 
will be the secondary  PK endpoints. I n addition, the difference of log -
transformed dose-
normalized baseline-adjusted AUClast and Cmax will be examined between the Japanese cohort 
estimated at the 50ug dose and the Non -Japanese cohort estimated at 100ug dose, as well as 
between the Japanese cohort estimated at the 25ug dose and the Non -Japanese cohort estimated 
at 100ug dose using an analy sis of variance model. The geometric mean ratio and its 90% CI  will 
be provided from the model.
9.8.2 Pharmacodynamic Analysis
All the PD analy ses will be performed using the PD set.
Pharmacod ynamic parameters will be computed from individual post dose values of serum 
calcium (uncorrected and corrected for serum albumin levels and both unadjusted and baseline -
adjusted) and phosphate using non- compartmental methods. Pharmacod ynamic parameters will 
be estimated based on both original and baseline -adjusted values of serum calcium and 
phosphate. The calcium-phosphate product will be computed. Baseline is defined as the pre- dose 
Shire CONFIDENTIAL Page 70
SHP634 -102 Protocol
Natpara 29Jan 2017
value on Day  1 for all subjects and, additionally , also on Day  4 and Day  7 for the subjects of 
Japanese descent. All calculations will be based on actual sampling times. Pharmacody namic 
parameters will be estimated based on non -compartmental anal yses and will include, but not be 
limited to, the following:
AUC last: Area under the curve from the time of dosing to the last measurable concentration
tmax: Time of maximum observed concentration sampled during a dosing interval
Emax:Maximum effect
TEmax: Time to maximum e ffect
9.8.3 Statistical Analysis of Pharmacodynamic Values
Individual values (original and baseline -adjusted) and PD parameters (original and baseline -
adjusted) of serum total calcium, albumin- corrected calcium, phosphate and the calcium -
phosphate (albumin -corrected calcium) product will be summarized with descriptive statistics 
(number, arithmetic mean, SD, CV%, median, minimum, maximum, geometric mean, and 
geometric CV%). Figures of individual and mean (±SD) concentration -time profiles of the 
original and base line-adjusted PD markers, serum calcium (total and corrected for serum 
albumin) and phosphate, will be generated. Mean plots will be overlaid for the Japanese cohort 
and the Non- Japanese cohort. Box -Whisker plots for selected PD parameters will be prepared
with the Japanese cohort and Non -Japanese cohort side by  side.
9.9 Safety Analyses
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities. The 
number of events, incidence, and percentage of treatment- emergent adverse events will b e 
calculated overall, b y system organ class, b y preferred term, and b y treatment group. 
Treatment -emergent adverse events will be further summarized by
 severit y and relationship to 
investigational product. Adverse events related to investigational product, AEs leading to 
withdrawal, SAEs, and deaths will be similarly  summarized/listed.
9.9.1 Safety Endpoint(s)
Clinical laboratory  tests, vital signs, and ECG findings will be summarized by  treatment group 
and visit as indicated below:
Number, severity , seriousness and causality  of treatment -emergent adverse events
Anti-PTH antibodies
Changes in vital signs, ECGs, and clinical laboratory  results (hematology , chemistry , and 
urinaly sis) from baseline to post baseline time points
9.9.2 Statistical Methodology for Safety Endp oint(s)
Safety  data, including TEAEs, laboratory  tests, anti -PTH antibodies, and vital signs, will be 
summarized. Descriptive statistics will be calculated for quantitative safet y data as well as for the 
difference from baseline, if applicable. Frequency  counts will be compiled for classification of 
Shire CONFIDENTIAL Page 71
SHP634 -102 Protocol
Natpara 29Jan 2017
qualitative safet y data. Direct safety comparisons between the two ethnic groups will be 
presented from the rhPTH(1 -84) 100µg dosing data. All other safet y data from the 25µg and 
50µg in the subjects of Japanese descent will be summarized and listed. Treatment-emergent 
AEs (TEAEs) are defined as AEs with start dates between the time of the first exposure to study  
drug and the last dose of the study  drug.
9.10 Other Analyses
No other anal yses are planned in this study .
Shire CONFIDENTIAL Page 72
SHP634 -102 Protocol
Natpara 29Jan 2017
10. SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, European Union 
(EU) Directive 2001/20/EC and its updates, and local ethical and legal requirements.
The name and address of each third- party vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH Good Clinical Practice (GCP) Guideline E6 ( 1996), EU 
Directive 2001/20/EC, as well as all applicable n ational and local laws and regulations.
Visits to sites are conducted by  representatives of the study  sponsor and/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and CRFs in accorda nce with current GCP and the respective local and 
inter/national government regulations and guidelines. Records and data may additionally  be 
reviewed b y auditors or by  regulatory  authorities.
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of
investigational product for shipmen t to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the investigator as necessary .
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact information.
10.1.4 Submission of Summary of Cli nical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s
) and to comply  with the
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for nonpediatric studies as per 
guidance. 
Shire CONFIDENTIAL Page 73
SHP634 -102 Protocol
Natpara 29Jan 2017
10.1.5 Study Suspension, Termination , and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appr opriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are 
available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigat or will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstra te such 
qualification. Curriculum vitae for investigators and sub- investigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subje ct’s consent, inform them of the subject’s participation in the study .
Agreement with the final clinical study  report is documented by  the signed and dated signature
of the principal investigator, in compliance with Directive 2001/83/EC as amended b y Direc tive 
2003/63/EC and I CH Guidance E3 ( 1995 ).
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and an y co-investigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only  those subjects 
who have met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the invest igator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The
investigator will also return all investigational product, containers, and other study materials to 
the sponsor. Upon study  completion, the inv estigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  the sponsor, applicable CRO, investigator, or, for 
Shire CONFIDENTIAL Page 74
SHP634 -102 Protocol
Natpara 29Jan 2017
multicenter studies, the coordinating principal investigator, according to national provisions, and 
will be documented in the investigator agreement.
10.2.3 Documentation and Retention of R ecords
10.2.3.1 Case Report Forms
Case report forms are supplied by  the sponsor or sponsor representative and should be handled in 
accordance with instructions from the sponsor or sponsor representative.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  onto the 
CRF.
All data sent to the sponsor must be endorsed b y the investigator.
The CRA/study  monitor will verify  the contents against the source data per the monitoring plan. 
If the data are unclear or contradictory , queries are sent for corrections or verification of data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during th is study  will include, but are not limited to the 
subject’s medical file and original clinical laboratory  reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor; the r espective national, 
local, or foreign regulatory  authorities; the I RB/EC; and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC, or r egulatory  inspectors) may  check the CRF 
entries against the source documents. The consent form includes a statement by  which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or IRB /EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory
 reports, X -rays, etc.). 
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorize d representative of an y regulatory  agency  (eg, the US Food and 
Drug Administration (FDA), European Medicines Agency  (EMA), United Kingdom (UK) 
Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained accord ing to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
Shire CONFIDENTIAL Page 75
SHP634 -102 Protocol
Natpara 29Jan 2017
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  representatives of, for example, the US FDA (as well as other US 
national and local regulatory  authorities), the EMA, the Medicines and Healthcare products 
Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
10.2.3.4 Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) ( 1998).
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informed consent from all study  
subjects prior to an y study -related procedures including screening assessments. All consent 
documentation must be in accordance with applicable regulations and GCP. Each subject or the 
subject’s legall y autho rized representative, as applicable, is requested to sign and date the subject 
informed consent form or a certified translation if applicable, after the subject has received and 
read (or been read) the written subject information and received an explanatio n of what the study  
involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, 
and the subject’s rights and responsibilities. A copy of the informed consent documentation (ie, a 
complete set of subject information sheets and fully  executed signature pages) must be given to 
the subject or the subject’s legally  authorized representative, as applicable. This document may  
require translation into the local language. Signed consent forms must remain in each subject’s 
study file and must be available for verification at any  time.
The principal investigator provides the sponsor with a cop y of the consent form that was 
reviewed b y the IRB/EC and received their favorable opinion/approval. A copy  of the IRB/EC’s 
written favora ble opinion/approval of these documents must be provided to the sponsor prior to 
the start of the stud y unless it is agreed to and documented (abiding b y regulatory guidelines and 
national provisions) prior to study  start that another part y (ie, sponsor or coordinating principal 
investigator) is responsible for this action. Additionally , if the IRB/EC requires modification of 
the sample subject information and consent document provided by  the sponsor, the 
documentation supporting this requirement must be pr ovided to the sponsor.
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant suppor ting 
Shire CONFIDENTIAL Page 76
SHP634 -102 Protocol
Natpara 29Jan 2017
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation .
The applicant for an EC opinion can be the sponsor or investigator for sites within the EU; for 
multicenter studies, the applicant can be the coordinating principal investigator or sponsor, 
according to national provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the clinical trial agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve an y 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor has received written 
IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  the sponsor or investigator, or, for multicenter 
studies, it can be done b y the coordinating principal investigator, according to national 
provisions. The investigator must also keep the local IRB/EC inform ed of any  serious and 
significant AEs.
10.4 Privacy and Confidentiality
All US
-based sites and laboratories or entities providing support for this study , must, where 
applicable, compl y with Health Insurance Portability  and Accountability  Act (HIPAA) of 1996. 
A site that is not a covered entity  as defined b y HIPAA must provide documentation of this fact 
to the sponsor.
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidel ines.
After subjects have consented to take part in the study , the sponsor and/or its representatives’ 
reviews their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed b y others including the following : independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market rhPTH(1 -84); national or local regulatory  authorities; and the IRB/EC which gave 
approval for the study  to proceed. The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a uniq ue identifying number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laboratory  results have been assigned to the correct subject).
Shire CONFIDENTIAL Page 77
SHP634 -102 Protocol
Natpara 29Jan 2017
The results of studies – containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that app lies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  regulatory or health authorities.
10.5 Study Results/Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as posit ive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee. The purpose of 
the publication steering committee is to act as a noncommercial bod y that advises or decides on 
dissemination of scientific study  data in accordance with the scope of this policy .
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  the 
publisher and cop yright law, the princip al investigator will own (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal suppl ements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  the sponsor that is necessary  to 
include in an y publication of study results, or necessary for other scholars to verify such stud y 
results . Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 d ays prior to 
submission for publication. If requested in writing by  Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 day s to 
allow for filing of a patent application.
If the stud y ispart of a multicenter study , the first publication of the study  results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analy zed study  results. If such a multicenter publi cation is not submitted to a 
journal for publication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
Shire CONFIDENTIAL Page 78
SHP634 -102 Protocol
Natpara 29Jan 2017
study  publication of the stud y results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless oth erwise required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
(ICMJE) current standards. Participation as an investigator does not confe r any rights to 
authorship of publications.
Shire CONFIDENTIAL Page 79
SHP634 -102 Protocol
Natpara 29Jan 2017
11. REFERENCES
Arlt, W, Fremerey , C, Callies, F, Reincke, M, Schneider, P, Timmermann, W & Allolio, B 2002. 
Well- being, mood and calcium homeostasis in patients with hy poparathy roidism receiving 
standard treatment with calcium and vitamin D. Eur J Endocrinol, 146, 215-22.
Avioli, L V 1974. The therapeutic approach to hy poparathy roidism. Am J Med, 57,34-42.
Behaghel, A & Donal, E 2011. Hy pocalcaemia -induced transient dilated cardiomy opath y in 
elderl y: a case report. Eur J Echocardiogr, 12,E38.
Bilezikian, JP, Khan, A, Potts, JT, Jr., Brandi, ML, Clarke, BL, Shoback, D, Juppner, H, 
D'amour, P, Fox, J, Rejnmark, L, Mosekilde, L, Rubin, MR, Dempster, D, Gafni, R, Collins, 
MT, Sliney , J & Sanders, J 201
1. Hy poparathy roidism in the adult: epidemiology , diagnosis, 
pathophy siology , target -organ involvement, treatment, and challenges for future research. J Bone 
Miner Res, 26,2317 -37.
Blaine, J, Chonchol, M & Levi, M 2015. Renal control of calcium, phosphate , and magnesium 
homeostasis. Clin J Am Soc Nephrol, 10,1257 -72.
Haussler, MR & Cord y, PE 1982. Metabolites and analogues of vitamin D. Which for what? 
Jama, 247, 841-4.
Page, C & Strunski, V 2007. Parathy roid risk in total thy roidectomy  for bilateral, ben ign, 
multinodular goitre: report of 351 surgical cases. J Laryngol Otol, 121, 237-41.
Powers, J, Joy , K, Ruscio, A & Lagast, H 2013. Prevalence and incidence of hy poparathy roidism 
in the United States using a large claims database. J Bone Miner Res, 28,2570-6.
Shoback, D 2008. Clinical practice. Hy poparathy roidism. N Engl J Med, 359, 391-403.
Thomusch, O, Machens, A, Sekulla, C, Ukkat, J, Brauckhoff, M & Dralle, H 2003. The impact 
of surgical technique on postoperative h ypoparathyroidism in bilateral th yroid surgery : a 
multivariate anal ysis of 5846 consecutive patients. 
Surgery, 133, 180-5.
Velasco, PJ, Manshadi, M, Breen, K & Lippmann, S 1999. Psy chiatric aspects of parath yroid 
disease. Psychosomatics, 40,486-90.
Winer, KK, Ko, CW, Rey nolds, JC, Dowdy , K,Keil, M, Peterson, D, Gerber, LH, Mcgarvey , C 
& Cutler, GB, Jr. 2003. Long- term treatment of hy poparathy roidism: a randomized controlled 
study  comparing parath yroid hormone -(1-34) versus calcitriol and calcium. J Clin Endocrinol 
Metab, 88,4214-20.
Winer, KK, Sinaii, N, Peterson, D, Sainz, B, Jr. & Cutler, GB, Jr. 2008. Effects of once versus 
twice -daily parath yroid hormone 1
-34 therapy  in children with hypoparathyroidism. J Clin 
Endocrinol Metab, 93,3389 -95.
Shire CONFIDENTIAL Page 80
SHP634 -102 Protocol
Natpara 29Jan 2017
Winer, KK, Yanovski, JA, Sarani, B & Cutler, G B, Jr. 1998. A randomized, cross -over trial of 
once -daily versus twice -daily  parathy roid hormone 1 -34 in treatment of h ypoparath yroidism. J 
Clin Endocrinol Metab, 83,3480 -6.
Zarnegar, R, Brunaud, L & Clark, OH 2003. Prevention, evaluation, and management of 
complications following thy roidectomy  for thy roid carcinoma. Endocrinol Metab Clin North Am,
32,483-502.
Shire CONFIDENTIAL Page 81
SHP634 -102 Protocol
Natpara 29Jan 2017
12. APPENDICES